
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml"
      xmlns:dc="http://purl.org/dc/terms/"
      xmlns:doi="http://dx.doi.org/"
      lang="en" xml:lang="en"
      itemscope itemtype="http://schema.org/Article"
      class="no-js">



<head prefix="og: http://ogp.me/ns#">
  <title>miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells</title>




<link rel="stylesheet" href="/resource/css/screen.css?e8097f76cb8c3b543f00c9cde49751d6"/>
  <!-- allows for  extra head tags -->


<!-- hello -->
<link rel="stylesheet" type="text/css"
      href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,600">

<link media="print" rel="stylesheet" type="text/css"  href="/resource/css/print.css"/>
    <script type="text/javascript">
        var siteUrlPrefix = "/plosone/";
    </script>
  <script src="/resource/js/vendor/modernizr-v2.7.1.js" type="text/javascript"></script>
  <script src="/resource/js/vendor/detectizr.min.js" type="text/javascript"></script>

  <link rel="shortcut icon" href="/resource/img/favicon.ico" type="image/x-icon"/>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>






  <link rel="canonical" href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0062170" />
  <meta name="description" content="Patients with triple-negative breast cancers (TNBCs) typically have a poor prognosis. TNBCs are characterized by their resistance to apoptosis, aggressive cellular proliferation, migration and invasion, and currently lack molecular markers and effective targeted therapy. Recently, miR-221/miR-222 have been shown to regulate ER&alpha; expression and ER&alpha;-mediated signaling in luminal breast cancer cells, and also to promote EMT in TNBCs. In this study, we characterized the role of miR-221 in a panel of TNBCs as compared to other breast cancer types. miR-221 knockdown not only blocked cell cycle progression, induced cell apoptosis, and inhibited cell proliferation in-vitro but it also inhibited in-vivo tumor growth by targeting p27kip1. Furthermore, miR-221 knockdown inhibited cell migration and invasion by altering E-cadherin expression, and its regulatory transcription factors Snail and Slug in human TNBC cell lines. Therefore, miR-221 functions as an oncogene and is essential in regulating tumorigenesis in TNBCs both in vitro as well as in vivo." />

  <meta name="citation_abstract" content="Patients with triple-negative breast cancers (TNBCs) typically have a poor prognosis. TNBCs are characterized by their resistance to apoptosis, aggressive cellular proliferation, migration and invasion, and currently lack molecular markers and effective targeted therapy. Recently, miR-221/miR-222 have been shown to regulate ER&alpha; expression and ER&alpha;-mediated signaling in luminal breast cancer cells, and also to promote EMT in TNBCs. In this study, we characterized the role of miR-221 in a panel of TNBCs as compared to other breast cancer types. miR-221 knockdown not only blocked cell cycle progression, induced cell apoptosis, and inhibited cell proliferation in-vitro but it also inhibited in-vivo tumor growth by targeting p27kip1. Furthermore, miR-221 knockdown inhibited cell migration and invasion by altering E-cadherin expression, and its regulatory transcription factors Snail and Slug in human TNBC cell lines. Therefore, miR-221 functions as an oncogene and is essential in regulating tumorigenesis in TNBCs both in vitro as well as in vivo.">


  <meta name="keywords" content="Breast cancer,MicroRNAs,Apoptosis,Vimentin,Cell proliferation,Slugs,Cell cycle inhibitors,Enzyme-linked immunoassays" />


<meta name="citation_doi" content="10.1371/journal.pone.0062170"/>
<meta name="citation_author" content="Rounak Nassirpour"/>
  <meta name="citation_author_institution" content="Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America"/>
<meta name="citation_author" content="Pramod P. Mehta"/>
  <meta name="citation_author_institution" content="Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America"/>
<meta name="citation_author" content="Sangita M. Baxi"/>
  <meta name="citation_author_institution" content="Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America"/>
<meta name="citation_author" content="Min-Jean Yin"/>
  <meta name="citation_author_institution" content="Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America"/>

<meta name="citation_title" content="miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells"/>
<meta itemprop="name" content="miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells"/>
<meta name="citation_journal_title" content="PLOS ONE"/>
<meta name="citation_journal_abbrev" content="PLOS ONE"/>
<meta name="citation_date" content="Apr 24, 2013"/>
<meta name="citation_firstpage" content="e62170"/>
<meta name="citation_issue" content="4"/>
<meta name="citation_volume" content="8"/>
<meta name="citation_issn" content="1932-6203"/>
<meta name="citation_publisher" content="Public Library of Science"/>

  <meta name="citation_pdf_url" content="https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0062170&type=printable">

  <meta name="citation_article_type" content="Research Article">

<meta name="dc.identifier" content="10.1371/journal.pone.0062170" />


  <meta name="twitter:card" content="summary" />
  <meta name="twitter:site" content="plosone"/>
    <meta name="twitter:title" content="miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells" />
    <meta property="twitter:description" content="Patients with triple-negative breast cancers (TNBCs) typically have a poor prognosis. TNBCs are characterized by their resistance to apoptosis, aggressive cellular proliferation, migration and invasion, and currently lack molecular markers and effective targeted therapy. Recently, miR-221/miR-222 have been shown to regulate ER&alpha; expression and ER&alpha;-mediated signaling in luminal breast cancer cells, and also to promote EMT in TNBCs. In this study, we characterized the role of miR-221 in a panel of TNBCs as compared to other breast cancer types. miR-221 knockdown not only blocked cell cycle progression, induced cell apoptosis, and inhibited cell proliferation in-vitro but it also inhibited in-vivo tumor growth by targeting p27kip1. Furthermore, miR-221 knockdown inhibited cell migration and invasion by altering E-cadherin expression, and its regulatory transcription factors Snail and Slug in human TNBC cell lines. Therefore, miR-221 functions as an oncogene and is essential in regulating tumorigenesis in TNBCs both in vitro as well as in vivo." />
    <meta property="twitter:image" content="https://journals.plos.org/plosone/article/figure/image?id=10.1371/journal.pone.0062170.g005&size=inline" />

<meta property="og:type" content="article" />
<meta property="og:url" content="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0062170"/>
<meta property="og:title" content="miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells"/>
<meta property="og:description" content="Patients with triple-negative breast cancers (TNBCs) typically have a poor prognosis. TNBCs are characterized by their resistance to apoptosis, aggressive cellular proliferation, migration and invasion, and currently lack molecular markers and effective targeted therapy. Recently, miR-221/miR-222 have been shown to regulate ER&alpha; expression and ER&alpha;-mediated signaling in luminal breast cancer cells, and also to promote EMT in TNBCs. In this study, we characterized the role of miR-221 in a panel of TNBCs as compared to other breast cancer types. miR-221 knockdown not only blocked cell cycle progression, induced cell apoptosis, and inhibited cell proliferation in-vitro but it also inhibited in-vivo tumor growth by targeting p27kip1. Furthermore, miR-221 knockdown inhibited cell migration and invasion by altering E-cadherin expression, and its regulatory transcription factors Snail and Slug in human TNBC cell lines. Therefore, miR-221 functions as an oncogene and is essential in regulating tumorigenesis in TNBCs both in vitro as well as in vivo."/>
<meta property="og:image" content="https://journals.plos.org/plosone/article/figure/image?id=10.1371/journal.pone.0062170.g005&size=inline"/>

<meta name="citation_reference" content="citation_title=MicroRNAs: genomics, biogenesis, mechanism, and function;citation_author=DP Bartel;citation_journal_title=Cell;citation_volume=116;citation_number=116;citation_first_page=281;citation_last_page=297;citation_publication_date=2004;"/>    
<meta name="citation_reference" content="citation_title=Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs;citation_author=LP Lim;citation_author=NC Lau;citation_author=P Garrett-Engele;citation_author=A Grimson;citation_author=JM Schelter;citation_journal_title=Nature;citation_volume=433;citation_number=433;citation_first_page=769;citation_last_page=773;citation_publication_date=2005;"/>    
<meta name="citation_reference" content="citation_title=Prediction of mammalian microRNA targets;citation_author=BP Lewis;citation_author=IH Shih;citation_author=MW Jones-Rhoades;citation_author=DP Bartel;citation_author=CB Burge;citation_journal_title=Cell;citation_volume=115;citation_number=115;citation_first_page=787;citation_last_page=798;citation_publication_date=2003;"/>    
<meta name="citation_reference" content="citation_title=Oncomirs - microRNAs with a role in cancer;citation_author=A Esquela-Kerscher;citation_author=FJ Slack;citation_journal_title=Nat Rev Cancer;citation_volume=6;citation_number=6;citation_first_page=259;citation_last_page=269;citation_publication_date=2006;"/>    
<meta name="citation_reference" content="citation_title=The functions of animal microRNAs;citation_author=V Ambros;citation_journal_title=Nature;citation_volume=431;citation_number=431;citation_first_page=350;citation_last_page=355;citation_publication_date=2004;"/>    
<meta name="citation_reference" content="citation_title=MicroRNA signatures in human cancers;citation_author=GA Calin;citation_author=CM Croce;citation_journal_title=Nat Rev Cancer;citation_volume=6;citation_number=6;citation_first_page=857;citation_last_page=866;citation_publication_date=2006;"/>    
<meta name="citation_reference" content="citation_title=MicroRNA expression profiles classify human cancers;citation_author=J Lu;citation_author=G Getz;citation_author=EA Miska;citation_author=E Alvarez-Saavedra;citation_author=J Lamb;citation_journal_title=Nature;citation_volume=435;citation_number=435;citation_first_page=834;citation_last_page=838;citation_publication_date=2005;"/>    
<meta name="citation_reference" content="citation_title=Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers;citation_author=GA Calin;citation_author=C Sevignani;citation_author=CD Dumitru;citation_author=T Hyslop;citation_author=E Noch;citation_journal_title=Proc Natl Acad Sci U S A;citation_volume=101;citation_number=101;citation_first_page=2999;citation_last_page=3004;citation_publication_date=2004;"/>    
<meta name="citation_reference" content="citation_title=Molecular portraits of human breast tumours;citation_author=CM Perou;citation_author=T Sorlie;citation_author=MB Eisen;citation_author=M van de Rijn;citation_author=SS Jeffrey;citation_journal_title=Nature;citation_volume=406;citation_number=406;citation_first_page=747;citation_last_page=752;citation_publication_date=2000;"/>    
<meta name="citation_reference" content="citation_title=Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications;citation_author=T Sorlie;citation_author=CM Perou;citation_author=R Tibshirani;citation_author=T Aas;citation_author=S Geisler;citation_journal_title=Proc Natl Acad Sci U S A;citation_volume=98;citation_number=98;citation_first_page=10869;citation_last_page=10874;citation_publication_date=2001;"/>    
<meta name="citation_reference" content="citation_title=Triple negative breast cancer: current understanding of biology and treatment options;citation_author=SP Kang;citation_author=M Martel;citation_author=LN Harris;citation_journal_title=Curr Opin Obstet Gynecol;citation_volume=20;citation_number=20;citation_first_page=40;citation_last_page=46;citation_publication_date=2008;"/>    
<meta name="citation_reference" content="citation_title=Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 &amp;apos;triple-negative&amp;apos; breast cancers;citation_author=FC Bidard;citation_author=R Conforti;citation_author=T Boulet;citation_author=S Michiels;citation_author=S Delaloge;citation_journal_title=Ann Oncol;citation_volume=18;citation_number=18;citation_first_page=1285;citation_last_page=1286;citation_publication_date=2007;"/>    
<meta name="citation_reference" content="citation_title=Triple-negative/basal-like breast cancer: review;citation_author=EA Rakha;citation_author=IO Ellis;citation_journal_title=Pathology;citation_volume=41;citation_number=41;citation_first_page=40;citation_last_page=47;citation_publication_date=2009;"/>    
<meta name="citation_reference" content="citation_title=Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study;citation_author=LA Carey;citation_author=CM Perou;citation_author=CA Livasy;citation_author=LG Dressler;citation_author=D Cowan;citation_journal_title=JAMA;citation_volume=295;citation_number=295;citation_first_page=2492;citation_last_page=2502;citation_publication_date=2006;"/>    
<meta name="citation_reference" content="citation_title=Triple-negative breast cancer: clinical features and patterns of recurrence;citation_author=R Dent;citation_author=M Trudeau;citation_author=KI Pritchard;citation_author=WM Hanna;citation_author=HK Kahn;citation_journal_title=Clin Cancer Res;citation_volume=13;citation_number=13;citation_first_page=4429;citation_last_page=4434;citation_publication_date=2007;"/>    
<meta name="citation_reference" content="citation_title=MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality;citation_author=L Gramantieri;citation_author=F Fornari;citation_author=M Ferracin;citation_author=A Veronese;citation_author=S Sabbioni;citation_journal_title=Clin Cancer Res;citation_volume=15;citation_number=15;citation_first_page=5073;citation_last_page=5081;citation_publication_date=2009;"/>    
<meta name="citation_reference" content="citation_title=miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1;citation_author=S Galardi;citation_author=N Mercatelli;citation_author=E Giorda;citation_author=S Massalini;citation_author=GV Frajese;citation_journal_title=J Biol Chem;citation_volume=282;citation_number=282;citation_first_page=23716;citation_last_page=23724;citation_publication_date=2007;"/>    
<meta name="citation_reference" content="citation_title=miR-221&amp;amp;222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation;citation_author=M Garofalo;citation_author=G Di Leva;citation_author=G Romano;citation_author=G Nuovo;citation_author=SS Suh;citation_journal_title=Cancer Cell;citation_volume=16;citation_number=16;citation_first_page=498;citation_last_page=509;citation_publication_date=2009;"/>    
<meta name="citation_reference" content="citation_title=MicroRNA-221 regulates chondrogenic differentiation through promoting proteosomal degradation of slug by targeting Mdm2;citation_author=D Kim;citation_author=J Song;citation_author=EJ Jin;citation_journal_title=J Biol Chem;citation_volume=285;citation_number=285;citation_first_page=26900;citation_last_page=26907;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines;citation_author=T Sun;citation_author=Q Wang;citation_author=S Balk;citation_author=M Brown;citation_author=GS Lee;citation_journal_title=Cancer Res;citation_volume=69;citation_number=69;citation_first_page=3356;citation_last_page=3363;citation_publication_date=2009;"/>    
<meta name="citation_reference" content="citation_title=PUMA is a novel target of miR-221/222 in human epithelial cancers;citation_author=C Zhang;citation_author=J Zhang;citation_author=A Zhang;citation_author=Y Wang;citation_author=L Han;citation_journal_title=Int J Oncol;citation_volume=37;citation_number=37;citation_first_page=1621;citation_last_page=1626;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer;citation_author=S Stinson;citation_author=MR Lackner;citation_author=AT Adai;citation_author=N Yu;citation_author=HJ Kim;citation_journal_title=Sci Signal;citation_volume=4;citation_number=4;citation_first_page=ra41;citation_publication_date=2011;"/>    
<meta name="citation_reference" content="citation_title=MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer;citation_author=JJ Zhao;citation_author=J Lin;citation_author=H Yang;citation_author=W Kong;citation_author=L He;citation_journal_title=J Biol Chem;citation_volume=283;citation_number=283;citation_first_page=31079;citation_last_page=31086;citation_publication_date=2008;"/>    
<meta name="citation_reference" content="citation_title=MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1;citation_author=TE Miller;citation_author=K Ghoshal;citation_author=B Ramaswamy;citation_author=S Roy;citation_author=J Datta;citation_journal_title=J Biol Chem;citation_volume=283;citation_number=283;citation_first_page=29897;citation_last_page=29903;citation_publication_date=2008;"/>    
<meta name="citation_reference" content="citation_title=MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways;citation_author=X Rao;citation_author=G Di Leva;citation_author=M Li;citation_author=F Fang;citation_author=C Devlin;citation_journal_title=Oncogene;citation_volume=30;citation_number=30;citation_first_page=1082;citation_last_page=1097;citation_publication_date=2011;"/>    
<meta name="citation_reference" content="citation_title=Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal;citation_author=Y Lu;citation_author=S Roy;citation_author=G Nuovo;citation_author=B Ramaswamy;citation_author=T Miller;citation_journal_title=J Biol Chem;citation_volume=286;citation_number=286;citation_first_page=42292;citation_last_page=42302;citation_publication_date=2011;"/>    
<meta name="citation_reference" content="citation_title=MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer;citation_author=DR Cochrane;citation_author=DM Cittelly;citation_author=EN Howe;citation_author=NS Spoelstra;citation_author=EL McKinsey;citation_journal_title=Horm Cancer;citation_volume=1;citation_number=1;citation_first_page=306;citation_last_page=319;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer;citation_author=J Radojicic;citation_author=A Zaravinos;citation_author=T Vrekoussis;citation_author=M Kafousi;citation_author=DA Spandidos;citation_journal_title=Cell Cycle;citation_volume=10;citation_number=10;citation_first_page=507;citation_last_page=517;citation_publication_date=2011;"/>    
<meta name="citation_reference" content="citation_title=The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity;citation_author=EN Howe;citation_author=DR Cochrane;citation_author=JK Richer;citation_journal_title=J Mammary Gland Biol Neoplasia;citation_volume=17;citation_number=17;citation_first_page=65;citation_last_page=77;citation_publication_date=2012;"/>    
<meta name="citation_reference" content="citation_title=Correlation between Slug transcription factor and miR-221 in MDA-MB-231 breast cancer cells;citation_author=E Lambertini;citation_author=A Lolli;citation_author=F Vezzali;citation_author=L Penolazzi;citation_author=R Gambari;citation_journal_title=BMC Cancer;citation_volume=12;citation_number=12;citation_first_page=445;citation_publication_date=2012;"/>    
<meta name="citation_reference" content="citation_title=Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation;citation_author=C le Sage;citation_author=R Nagel;citation_author=DA Egan;citation_author=M Schrier;citation_author=E Mesman;citation_journal_title=EMBO J;citation_volume=26;citation_number=26;citation_first_page=3699;citation_last_page=3708;citation_publication_date=2007;"/>    
<meta name="citation_reference" content="citation_title=MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma;citation_author=F Fornari;citation_author=L Gramantieri;citation_author=M Ferracin;citation_author=A Veronese;citation_author=S Sabbioni;citation_journal_title=Oncogene;citation_volume=27;citation_number=27;citation_first_page=5651;citation_last_page=5661;citation_publication_date=2008;"/>    
<meta name="citation_reference" content="citation_title=Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors;citation_author=Z Lu;citation_author=T Hunter;citation_journal_title=Cell Cycle;citation_volume=9;citation_number=9;citation_first_page=2342;citation_last_page=2352;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=Molecular mechanisms of caspase regulation during apoptosis;citation_author=SJ Riedl;citation_author=Y Shi;citation_journal_title=Nat Rev Mol Cell Biol;citation_volume=5;citation_number=5;citation_first_page=897;citation_last_page=907;citation_publication_date=2004;"/>    
<meta name="citation_reference" content="citation_title=Mitochondria and cell death: outer membrane permeabilization and beyond;citation_author=SW Tait;citation_author=DR Green;citation_journal_title=Nat Rev Mol Cell Biol;citation_volume=11;citation_number=11;citation_first_page=621;citation_last_page=632;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=Epithelial-mesenchymal transitions in development and disease;citation_author=JP Thiery;citation_author=H Acloque;citation_author=RY Huang;citation_author=MA Nieto;citation_journal_title=Cell;citation_volume=139;citation_number=139;citation_first_page=871;citation_last_page=890;citation_publication_date=2009;"/>    
<meta name="citation_reference" content="citation_title=EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness;citation_author=E Sanchez-Tillo;citation_author=Y Liu;citation_author=O de Barrios;citation_author=L Siles;citation_author=L Fanlo;citation_journal_title=Cell Mol Life Sci;citation_volume=69;citation_number=69;citation_first_page=3429;citation_last_page=3456;citation_publication_date=2012;"/>    
<meta name="citation_reference" content="citation_title=The SLUG zinc-finger protein represses E-cadherin in breast cancer;citation_author=KM Hajra;citation_author=DY Chen;citation_author=ER Fearon;citation_journal_title=Cancer Res;citation_volume=62;citation_number=62;citation_first_page=1613;citation_last_page=1618;citation_publication_date=2002;"/>    
<meta name="citation_reference" content="citation_title=Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs;citation_author=IK Guttilla;citation_author=KN Phoenix;citation_author=X Hong;citation_author=JS Tirnauer;citation_author=KP Claffey;citation_journal_title=Breast Cancer Res Treat;citation_volume=132;citation_number=132;citation_first_page=75;citation_last_page=85;citation_publication_date=2012;"/>    


<!-- DoubleClick overall ad setup script -->
<script type='text/javascript'>
  var googletag = googletag || {};
  googletag.cmd = googletag.cmd || [];
  (function() {
    var gads = document.createElement('script');
    gads.async = true;
    gads.type = 'text/javascript';
    var useSSL = 'https:' == document.location.protocol;
    gads.src = (useSSL ? 'https:' : 'http:') +
        '//www.googletagservices.com/tag/js/gpt.js';
    var node = document.getElementsByTagName('script')[0];
    node.parentNode.insertBefore(gads, node);
  })();
</script>

<!-- DoubleClick ad slot setup script -->

  <script id="doubleClickSetupScript" type='text/javascript'>
    googletag.cmd.push(function() {
  googletag.defineSlot('/75507958/PONE_728x90_ATF', [728, 90], 'div-gpt-ad-1458247671871-0').addService(googletag.pubads());
  googletag.defineSlot('/75507958/PONE_160x600_BTF', [160, 600], 'div-gpt-ad-1458247671871-1').addService(googletag.pubads());
      var personalizedAds = window.plosCookieConsent && window.plosCookieConsent.hasConsented('advertising');
      googletag.pubads().setRequestNonPersonalizedAds(personalizedAds ? 0 : 1);
      googletag.pubads().enableSingleRequest();
      googletag.enableServices();
    });
  </script>



<script type="text/javascript">
    var WombatConfig = WombatConfig || {};
    WombatConfig.journalKey = "PLoSONE";
    WombatConfig.figurePath = "/plosone/article/figure/image";
    WombatConfig.figShareInstitutionString = "plos";
    WombatConfig.doiResolverPrefix = "https://dx.plos.org/";
</script>

<script type="text/javascript">
  var WombatConfig = WombatConfig || {};
  WombatConfig.metrics = WombatConfig.metrics || {};
  WombatConfig.metrics.referenceUrl      = "http://lagotto.io/plos";
  WombatConfig.metrics.googleScholarUrl  = "https://scholar.google.com/scholar";
  WombatConfig.metrics.googleScholarCitationUrl  = WombatConfig.metrics.googleScholarUrl + "?hl=en&lr=&q=";
  WombatConfig.metrics.crossrefUrl  = "https://www.crossref.org";
</script>
<script defer="defer" src="/resource/js/defer.js?df22e765dd76f625eb58"></script><script src="/resource/js/sync.js?df22e765dd76f625eb58"></script>
<script src="https://ajax.googleapis.com/ajax/libs/jquery/2.1.4/jquery.min.js"></script>

          <script type="text/javascript" src="https://widgets.figshare.com/static/figshare.js"></script>

<script src="/resource/js/vendor/fastclick/lib/fastclick.js" type="text/javascript"></script>
<script src="/resource/js/vendor/foundation/foundation.js" type="text/javascript"></script>
<script src="/resource/js/vendor/underscore-min.js" type="text/javascript"></script>
<script src="/resource/js/vendor/underscore.string.min.js" type="text/javascript"></script>
<script src="/resource/js/vendor/moment.js" type="text/javascript"></script>


<script src="/resource/js/vendor/jquery-ui-effects.min.js" type="text/javascript"></script>

<script src="/resource/js/vendor/foundation/foundation.tooltip.js" type="text/javascript"></script>
<script src="/resource/js/vendor/foundation/foundation.dropdown.js" type="text/javascript"></script>
<script src="/resource/js/vendor/foundation/foundation.tab.js" type="text/javascript"></script>
<script src="/resource/js/vendor/foundation/foundation.reveal.js" type="text/javascript"></script>
<script src="/resource/js/vendor/foundation/foundation.slider.js" type="text/javascript"></script>

<script src="/resource/js/util/utils.js" type="text/javascript"></script>
<script src="/resource/js/components/toggle.js" type="text/javascript"></script>
<script src="/resource/js/components/truncate_elem.js" type="text/javascript"></script>
<script src="/resource/js/components/tooltip_hover.js" type="text/javascript"></script>
<script src="/resource/js/vendor/jquery.dotdotdot.js" type="text/javascript"></script>

<!--For Google Tag manager to be able to track site information  -->
<script>

  dataLayer = [{
    'mobileSite': 'false',
    'desktopSite': 'true'
  }];

</script>

</head>

<body class="article plosone">


<!-- Google Tag Manager -->
<script>
  var gaDisable = 'ga-disable-UA-76325259-';
  var consented = !(window.plosCookieConsent && window.plosCookieConsent.hasConsented('analytics'));
  for(var i=0;i<100;i++) { //This will break if we ever support 100+ journals (*insert Oh no! Anyway... meme*)
    window[gaDisable + i] = consented;
  }
</script>
<noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-TP26BH"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<script>
  (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
    new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
    j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
    '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-TP26BH');
</script>

<noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-MQQMGF"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
    new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
    j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
    '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-MQQMGF');</script>
<!-- End Google Tag Manager -->

<!-- New Relic -->
<script type="text/javascript">
  ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}};
  window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var o=e[n]={exports:{}};t[n][0].call(o.exports,function(e){var o=t[n][1][e];return r(o||e)},o,o.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<n.length;o++)r(n[o]);return r}({1:[function(t,e,n){function r(t){try{s.console&&console.log(t)}catch(e){}}var o,i=t("ee"),a=t(32),s={};try{o=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(s.console=!0,o.indexOf("dev")!==-1&&(s.dev=!0),o.indexOf("nr_dev")!==-1&&(s.nrDev=!0))}catch(c){}s.nrDev&&i.on("internal-error",function(t){r(t.stack)}),s.dev&&i.on("fn-err",function(t,e,n){r(n.stack)}),s.dev&&(r("NR AGENT IN DEVELOPMENT MODE"),r("flags: "+a(s,function(t,e){return t}).join(", ")))},{}],2:[function(t,e,n){function r(t,e,n,r,s){try{l?l-=1:o(s||new UncaughtException(t,e,n),!0)}catch(f){try{i("ierr",[f,c.now(),!0])}catch(d){}}return"function"==typeof u&&u.apply(this,a(arguments))}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function o(t,e){var n=e?null:c.now();i("err",[t,n])}var i=t("handle"),a=t(33),s=t("ee"),c=t("loader"),f=t("gos"),u=window.onerror,d=!1,p="nr@seenError";if(!c.disabled){var l=0;c.features.err=!0,t(1),window.onerror=r;try{throw new Error}catch(h){"stack"in h&&(t(14),t(13),"addEventListener"in window&&t(7),c.xhrWrappable&&t(15),d=!0)}s.on("fn-start",function(t,e,n){d&&(l+=1)}),s.on("fn-err",function(t,e,n){d&&!n[p]&&(f(n,p,function(){return!0}),this.thrown=!0,o(n))}),s.on("fn-end",function(){d&&!this.thrown&&l>0&&(l-=1)}),s.on("internal-error",function(t){i("ierr",[t,c.now(),!0])})}},{}],3:[function(t,e,n){var r=t("loader");r.disabled||(r.features.ins=!0)},{}],4:[function(t,e,n){function r(){U++,L=g.hash,this[u]=y.now()}function o(){U--,g.hash!==L&&i(0,!0);var t=y.now();this[h]=~~this[h]+t-this[u],this[d]=t}function i(t,e){E.emit("newURL",[""+g,e])}function a(t,e){t.on(e,function(){this[e]=y.now()})}var s="-start",c="-end",f="-body",u="fn"+s,d="fn"+c,p="cb"+s,l="cb"+c,h="jsTime",m="fetch",v="addEventListener",w=window,g=w.location,y=t("loader");if(w[v]&&y.xhrWrappable&&!y.disabled){var x=t(11),b=t(12),E=t(9),R=t(7),O=t(14),T=t(8),P=t(15),S=t(10),M=t("ee"),N=M.get("tracer"),C=t(23);t(17),y.features.spa=!0;var L,U=0;M.on(u,r),b.on(p,r),S.on(p,r),M.on(d,o),b.on(l,o),S.on(l,o),M.buffer([u,d,"xhr-resolved"]),R.buffer([u]),O.buffer(["setTimeout"+c,"clearTimeout"+s,u]),P.buffer([u,"new-xhr","send-xhr"+s]),T.buffer([m+s,m+"-done",m+f+s,m+f+c]),E.buffer(["newURL"]),x.buffer([u]),b.buffer(["propagate",p,l,"executor-err","resolve"+s]),N.buffer([u,"no-"+u]),S.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"]),a(T,m+s),a(T,m+"-done"),a(S,"new-jsonp"),a(S,"jsonp-end"),a(S,"cb-start"),E.on("pushState-end",i),E.on("replaceState-end",i),w[v]("hashchange",i,C(!0)),w[v]("load",i,C(!0)),w[v]("popstate",function(){i(0,U>1)},C(!0))}},{}],5:[function(t,e,n){function r(){var t=new PerformanceObserver(function(t,e){var n=t.getEntries();s(v,[n])});try{t.observe({entryTypes:["resource"]})}catch(e){}}function o(t){if(s(v,[window.performance.getEntriesByType(w)]),window.performance["c"+p])try{window.performance[h](m,o,!1)}catch(t){}else try{window.performance[h]("webkit"+m,o,!1)}catch(t){}}function i(t){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var a=t("ee"),s=t("handle"),c=t(14),f=t(13),u=t(6),d=t(23),p="learResourceTimings",l="addEventListener",h="removeEventListener",m="resourcetimingbufferfull",v="bstResource",w="resource",g="-start",y="-end",x="fn"+g,b="fn"+y,E="bstTimer",R="pushState",O=t("loader");if(!O.disabled){O.features.stn=!0,t(9),"addEventListener"in window&&t(7);var T=NREUM.o.EV;a.on(x,function(t,e){var n=t[0];n instanceof T&&(this.bstStart=O.now())}),a.on(b,function(t,e){var n=t[0];n instanceof T&&s("bst",[n,e,this.bstStart,O.now()])}),c.on(x,function(t,e,n){this.bstStart=O.now(),this.bstType=n}),c.on(b,function(t,e){s(E,[e,this.bstStart,O.now(),this.bstType])}),f.on(x,function(){this.bstStart=O.now()}),f.on(b,function(t,e){s(E,[e,this.bstStart,O.now(),"requestAnimationFrame"])}),a.on(R+g,function(t){this.time=O.now(),this.startPath=location.pathname+location.hash}),a.on(R+y,function(t){s("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),u()?(s(v,[window.performance.getEntriesByType("resource")]),r()):l in window.performance&&(window.performance["c"+p]?window.performance[l](m,o,d(!1)):window.performance[l]("webkit"+m,o,d(!1))),document[l]("scroll",i,d(!1)),document[l]("keypress",i,d(!1)),document[l]("click",i,d(!1))}}},{}],6:[function(t,e,n){e.exports=function(){return"PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver}},{}],7:[function(t,e,n){function r(t){for(var e=t;e&&!e.hasOwnProperty(u);)e=Object.getPrototypeOf(e);e&&o(e)}function o(t){s.inPlace(t,[u,d],"-",i)}function i(t,e){return t[1]}var a=t("ee").get("events"),s=t("wrap-function")(a,!0),c=t("gos"),f=XMLHttpRequest,u="addEventListener",d="removeEventListener";e.exports=a,"getPrototypeOf"in Object?(r(document),r(window),r(f.prototype)):f.prototype.hasOwnProperty(u)&&(o(window),o(f.prototype)),a.on(u+"-start",function(t,e){var n=t[1];if(null!==n&&("function"==typeof n||"object"==typeof n)){var r=c(n,"nr@wrapped",function(){function t(){if("function"==typeof n.handleEvent)return n.handleEvent.apply(n,arguments)}var e={object:t,"function":n}[typeof n];return e?s(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=t[1]=r}}),a.on(d+"-start",function(t){t[1]=this.wrapped||t[1]})},{}],8:[function(t,e,n){function r(t,e,n){var r=t[e];"function"==typeof r&&(t[e]=function(){var t=i(arguments),e={};o.emit(n+"before-start",[t],e);var a;e[m]&&e[m].dt&&(a=e[m].dt);var s=r.apply(this,t);return o.emit(n+"start",[t,a],s),s.then(function(t){return o.emit(n+"end",[null,t],s),t},function(t){throw o.emit(n+"end",[t],s),t})})}var o=t("ee").get("fetch"),i=t(33),a=t(32);e.exports=o;var s=window,c="fetch-",f=c+"body-",u=["arrayBuffer","blob","json","text","formData"],d=s.Request,p=s.Response,l=s.fetch,h="prototype",m="nr@context";d&&p&&l&&(a(u,function(t,e){r(d[h],e,f),r(p[h],e,f)}),r(s,"fetch",c),o.on(c+"end",function(t,e){var n=this;if(e){var r=e.headers.get("content-length");null!==r&&(n.rxSize=r),o.emit(c+"done",[null,e],n)}else o.emit(c+"done",[t],n)}))},{}],9:[function(t,e,n){var r=t("ee").get("history"),o=t("wrap-function")(r);e.exports=r;var i=window.history&&window.history.constructor&&window.history.constructor.prototype,a=window.history;i&&i.pushState&&i.replaceState&&(a=i),o.inPlace(a,["pushState","replaceState"],"-")},{}],10:[function(t,e,n){function r(t){function e(){f.emit("jsonp-end",[],l),t.removeEventListener("load",e,c(!1)),t.removeEventListener("error",n,c(!1))}function n(){f.emit("jsonp-error",[],l),f.emit("jsonp-end",[],l),t.removeEventListener("load",e,c(!1)),t.removeEventListener("error",n,c(!1))}var r=t&&"string"==typeof t.nodeName&&"script"===t.nodeName.toLowerCase();if(r){var o="function"==typeof t.addEventListener;if(o){var a=i(t.src);if(a){var d=s(a),p="function"==typeof d.parent[d.key];if(p){var l={};u.inPlace(d.parent,[d.key],"cb-",l),t.addEventListener("load",e,c(!1)),t.addEventListener("error",n,c(!1)),f.emit("new-jsonp",[t.src],l)}}}}}function o(){return"addEventListener"in window}function i(t){var e=t.match(d);return e?e[1]:null}function a(t,e){var n=t.match(l),r=n[1],o=n[3];return o?a(o,e[r]):e[r]}function s(t){var e=t.match(p);return e&&e.length>=3?{key:e[2],parent:a(e[1],window)}:{key:t,parent:window}}var c=t(23),f=t("ee").get("jsonp"),u=t("wrap-function")(f);if(e.exports=f,o()){var d=/[?&](?:callback|cb)=([^&#]+)/,p=/(.*)\.([^.]+)/,l=/^(\w+)(\.|$)(.*)$/,h=["appendChild","insertBefore","replaceChild"];Node&&Node.prototype&&Node.prototype.appendChild?u.inPlace(Node.prototype,h,"dom-"):(u.inPlace(HTMLElement.prototype,h,"dom-"),u.inPlace(HTMLHeadElement.prototype,h,"dom-"),u.inPlace(HTMLBodyElement.prototype,h,"dom-")),f.on("dom-start",function(t){r(t[0])})}},{}],11:[function(t,e,n){var r=t("ee").get("mutation"),o=t("wrap-function")(r),i=NREUM.o.MO;e.exports=r,i&&(window.MutationObserver=function(t){return this instanceof i?new i(o(t,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype)},{}],12:[function(t,e,n){function r(t){var e=i.context(),n=s(t,"executor-",e,null,!1),r=new f(n);return i.context(r).getCtx=function(){return e},r}var o=t("wrap-function"),i=t("ee").get("promise"),a=t("ee").getOrSetContext,s=o(i),c=t(32),f=NREUM.o.PR;e.exports=i,f&&(window.Promise=r,["all","race"].forEach(function(t){var e=f[t];f[t]=function(n){function r(t){return function(){i.emit("propagate",[null,!o],a,!1,!1),o=o||!t}}var o=!1;c(n,function(e,n){Promise.resolve(n).then(r("all"===t),r(!1))});var a=e.apply(f,arguments),s=f.resolve(a);return s}}),["resolve","reject"].forEach(function(t){var e=f[t];f[t]=function(t){var n=e.apply(f,arguments);return t!==n&&i.emit("propagate",[t,!0],n,!1,!1),n}}),f.prototype["catch"]=function(t){return this.then(null,t)},f.prototype=Object.create(f.prototype,{constructor:{value:r}}),c(Object.getOwnPropertyNames(f),function(t,e){try{r[e]=f[e]}catch(n){}}),o.wrapInPlace(f.prototype,"then",function(t){return function(){var e=this,n=o.argsToArray.apply(this,arguments),r=a(e);r.promise=e,n[0]=s(n[0],"cb-",r,null,!1),n[1]=s(n[1],"cb-",r,null,!1);var c=t.apply(this,n);return r.nextPromise=c,i.emit("propagate",[e,!0],c,!1,!1),c}}),i.on("executor-start",function(t){t[0]=s(t[0],"resolve-",this,null,!1),t[1]=s(t[1],"resolve-",this,null,!1)}),i.on("executor-err",function(t,e,n){t[1](n)}),i.on("cb-end",function(t,e,n){i.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),i.on("propagate",function(t,e,n){this.getCtx&&!e||(this.getCtx=function(){if(t instanceof Promise)var e=i.context(t);return e&&e.getCtx?e.getCtx():this})}),r.toString=function(){return""+f})},{}],13:[function(t,e,n){var r=t("ee").get("raf"),o=t("wrap-function")(r),i="equestAnimationFrame";e.exports=r,o.inPlace(window,["r"+i,"mozR"+i,"webkitR"+i,"msR"+i],"raf-"),r.on("raf-start",function(t){t[0]=o(t[0],"fn-")})},{}],14:[function(t,e,n){function r(t,e,n){t[0]=a(t[0],"fn-",null,n)}function o(t,e,n){this.method=n,this.timerDuration=isNaN(t[1])?0:+t[1],t[0]=a(t[0],"fn-",this,n)}var i=t("ee").get("timer"),a=t("wrap-function")(i),s="setTimeout",c="setInterval",f="clearTimeout",u="-start",d="-";e.exports=i,a.inPlace(window,[s,"setImmediate"],s+d),a.inPlace(window,[c],c+d),a.inPlace(window,[f,"clearImmediate"],f+d),i.on(c+u,r),i.on(s+u,o)},{}],15:[function(t,e,n){function r(t,e){d.inPlace(e,["onreadystatechange"],"fn-",s)}function o(){var t=this,e=u.context(t);t.readyState>3&&!e.resolved&&(e.resolved=!0,u.emit("xhr-resolved",[],t)),d.inPlace(t,y,"fn-",s)}function i(t){x.push(t),m&&(E?E.then(a):w?w(a):(R=-R,O.data=R))}function a(){for(var t=0;t<x.length;t++)r([],x[t]);x.length&&(x=[])}function s(t,e){return e}function c(t,e){for(var n in t)e[n]=t[n];return e}t(7);var f=t("ee"),u=f.get("xhr"),d=t("wrap-function")(u),p=t(23),l=NREUM.o,h=l.XHR,m=l.MO,v=l.PR,w=l.SI,g="readystatechange",y=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],x=[];e.exports=u;var b=window.XMLHttpRequest=function(t){var e=new h(t);try{u.emit("new-xhr",[e],e),e.addEventListener(g,o,p(!1))}catch(n){try{u.emit("internal-error",[n])}catch(r){}}return e};if(c(h,b),b.prototype=h.prototype,d.inPlace(b.prototype,["open","send"],"-xhr-",s),u.on("send-xhr-start",function(t,e){r(t,e),i(e)}),u.on("open-xhr-start",r),m){var E=v&&v.resolve();if(!w&&!v){var R=1,O=document.createTextNode(R);new m(a).observe(O,{characterData:!0})}}else f.on("fn-end",function(t){t[0]&&t[0].type===g||a()})},{}],16:[function(t,e,n){function r(t){if(!s(t))return null;var e=window.NREUM;if(!e.loader_config)return null;var n=(e.loader_config.accountID||"").toString()||null,r=(e.loader_config.agentID||"").toString()||null,f=(e.loader_config.trustKey||"").toString()||null;if(!n||!r)return null;var h=l.generateSpanId(),m=l.generateTraceId(),v=Date.now(),w={spanId:h,traceId:m,timestamp:v};return(t.sameOrigin||c(t)&&p())&&(w.traceContextParentHeader=o(h,m),w.traceContextStateHeader=i(h,v,n,r,f)),(t.sameOrigin&&!u()||!t.sameOrigin&&c(t)&&d())&&(w.newrelicHeader=a(h,m,v,n,r,f)),w}function o(t,e){return"00-"+e+"-"+t+"-01"}function i(t,e,n,r,o){var i=0,a="",s=1,c="",f="";return o+"@nr="+i+"-"+s+"-"+n+"-"+r+"-"+t+"-"+a+"-"+c+"-"+f+"-"+e}function a(t,e,n,r,o,i){var a="btoa"in window&&"function"==typeof window.btoa;if(!a)return null;var s={v:[0,1],d:{ty:"Browser",ac:r,ap:o,id:t,tr:e,ti:n}};return i&&r!==i&&(s.d.tk=i),btoa(JSON.stringify(s))}function s(t){return f()&&c(t)}function c(t){var e=!1,n={};if("init"in NREUM&&"distributed_tracing"in NREUM.init&&(n=NREUM.init.distributed_tracing),t.sameOrigin)e=!0;else if(n.allowed_origins instanceof Array)for(var r=0;r<n.allowed_origins.length;r++){var o=h(n.allowed_origins[r]);if(t.hostname===o.hostname&&t.protocol===o.protocol&&t.port===o.port){e=!0;break}}return e}function f(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.enabled}function u(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.exclude_newrelic_header}function d(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&NREUM.init.distributed_tracing.cors_use_newrelic_header!==!1}function p(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.cors_use_tracecontext_headers}var l=t(29),h=t(18);e.exports={generateTracePayload:r,shouldGenerateTrace:s}},{}],17:[function(t,e,n){function r(t){var e=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var r=0;r<p;r++)t.removeEventListener(d[r],this.listener,!1);e.aborted||(n.duration=a.now()-this.startTime,this.loadCaptureCalled||4!==t.readyState?null==e.status&&(e.status=0):i(this,t),n.cbTime=this.cbTime,s("xhr",[e,n,this.startTime,this.endTime,"xhr"],this))}}function o(t,e){var n=c(e),r=t.params;r.hostname=n.hostname,r.port=n.port,r.protocol=n.protocol,r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.parsedOrigin=n,t.sameOrigin=n.sameOrigin}function i(t,e){t.params.status=e.status;var n=v(e,t.lastSize);if(n&&(t.metrics.rxSize=n),t.sameOrigin){var r=e.getResponseHeader("X-NewRelic-App-Data");r&&(t.params.cat=r.split(", ").pop())}t.loadCaptureCalled=!0}var a=t("loader");if(a.xhrWrappable&&!a.disabled){var s=t("handle"),c=t(18),f=t(16).generateTracePayload,u=t("ee"),d=["load","error","abort","timeout"],p=d.length,l=t("id"),h=t(24),m=t(22),v=t(19),w=t(23),g=NREUM.o.REQ,y=window.XMLHttpRequest;a.features.xhr=!0,t(15),t(8),u.on("new-xhr",function(t){var e=this;e.totalCbs=0,e.called=0,e.cbTime=0,e.end=r,e.ended=!1,e.xhrGuids={},e.lastSize=null,e.loadCaptureCalled=!1,e.params=this.params||{},e.metrics=this.metrics||{},t.addEventListener("load",function(n){i(e,t)},w(!1)),h&&(h>34||h<10)||t.addEventListener("progress",function(t){e.lastSize=t.loaded},w(!1))}),u.on("open-xhr-start",function(t){this.params={method:t[0]},o(this,t[1]),this.metrics={}}),u.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid);var n=f(this.parsedOrigin);if(n){var r=!1;n.newrelicHeader&&(e.setRequestHeader("newrelic",n.newrelicHeader),r=!0),n.traceContextParentHeader&&(e.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&e.setRequestHeader("tracestate",n.traceContextStateHeader),r=!0),r&&(this.dt=n)}}),u.on("send-xhr-start",function(t,e){var n=this.metrics,r=t[0],o=this;if(n&&r){var i=m(r);i&&(n.txSize=i)}this.startTime=a.now(),this.listener=function(t){try{"abort"!==t.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==t.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof e.onload))&&o.end(e)}catch(n){try{u.emit("internal-error",[n])}catch(r){}}};for(var s=0;s<p;s++)e.addEventListener(d[s],this.listener,w(!1))}),u.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),u.on("xhr-load-added",function(t,e){var n=""+l(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),u.on("xhr-load-removed",function(t,e){var n=""+l(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),u.on("xhr-resolved",function(){this.endTime=a.now()}),u.on("addEventListener-end",function(t,e){e instanceof y&&"load"===t[0]&&u.emit("xhr-load-added",[t[1],t[2]],e)}),u.on("removeEventListener-end",function(t,e){e instanceof y&&"load"===t[0]&&u.emit("xhr-load-removed",[t[1],t[2]],e)}),u.on("fn-start",function(t,e,n){e instanceof y&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=a.now()))}),u.on("fn-end",function(t,e){this.xhrCbStart&&u.emit("xhr-cb-time",[a.now()-this.xhrCbStart,this.onload,e],e)}),u.on("fetch-before-start",function(t){function e(t,e){var n=!1;return e.newrelicHeader&&(t.set("newrelic",e.newrelicHeader),n=!0),e.traceContextParentHeader&&(t.set("traceparent",e.traceContextParentHeader),e.traceContextStateHeader&&t.set("tracestate",e.traceContextStateHeader),n=!0),n}var n,r=t[1]||{};"string"==typeof t[0]?n=t[0]:t[0]&&t[0].url?n=t[0].url:window.URL&&t[0]&&t[0]instanceof URL&&(n=t[0].href),n&&(this.parsedOrigin=c(n),this.sameOrigin=this.parsedOrigin.sameOrigin);var o=f(this.parsedOrigin);if(o&&(o.newrelicHeader||o.traceContextParentHeader))if("string"==typeof t[0]||window.URL&&t[0]&&t[0]instanceof URL){var i={};for(var a in r)i[a]=r[a];i.headers=new Headers(r.headers||{}),e(i.headers,o)&&(this.dt=o),t.length>1?t[1]=i:t.push(i)}else t[0]&&t[0].headers&&e(t[0].headers,o)&&(this.dt=o)}),u.on("fetch-start",function(t,e){this.params={},this.metrics={},this.startTime=a.now(),this.dt=e,t.length>=1&&(this.target=t[0]),t.length>=2&&(this.opts=t[1]);var n,r=this.opts||{},i=this.target;"string"==typeof i?n=i:"object"==typeof i&&i instanceof g?n=i.url:window.URL&&"object"==typeof i&&i instanceof URL&&(n=i.href),o(this,n);var s=(""+(i&&i instanceof g&&i.method||r.method||"GET")).toUpperCase();this.params.method=s,this.txSize=m(r.body)||0}),u.on("fetch-done",function(t,e){this.endTime=a.now(),this.params||(this.params={}),this.params.status=e?e.status:0;var n;"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var r={txSize:this.txSize,rxSize:n,duration:a.now()-this.startTime};s("xhr",[this.params,r,this.startTime,this.endTime,"fetch"],this)})}},{}],18:[function(t,e,n){var r={};e.exports=function(t){if(t in r)return r[t];var e=document.createElement("a"),n=window.location,o={};e.href=t,o.port=e.port;var i=e.href.split("://");!o.port&&i[1]&&(o.port=i[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===i[0]?"443":"80"),o.hostname=e.hostname||n.hostname,o.pathname=e.pathname,o.protocol=i[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var a=!e.protocol||":"===e.protocol||e.protocol===n.protocol,s=e.hostname===document.domain&&e.port===n.port;return o.sameOrigin=a&&(!e.hostname||s),"/"===o.pathname&&(r[t]=o),o}},{}],19:[function(t,e,n){function r(t,e){var n=t.responseType;return"json"===n&&null!==e?e:"arraybuffer"===n||"blob"===n||"json"===n?o(t.response):"text"===n||""===n||void 0===n?o(t.responseText):void 0}var o=t(22);e.exports=r},{}],20:[function(t,e,n){function r(){}function o(t,e,n,r){return function(){return u.recordSupportability("API/"+e+"/called"),i(t+e,[f.now()].concat(s(arguments)),n?null:this,r),n?void 0:this}}var i=t("handle"),a=t(32),s=t(33),c=t("ee").get("tracer"),f=t("loader"),u=t(25),d=NREUM;"undefined"==typeof window.newrelic&&(newrelic=d);var p=["setPageViewName","setCustomAttribute","setErrorHandler","finished","addToTrace","inlineHit","addRelease"],l="api-",h=l+"ixn-";a(p,function(t,e){d[e]=o(l,e,!0,"api")}),d.addPageAction=o(l,"addPageAction",!0),d.setCurrentRouteName=o(l,"routeName",!0),e.exports=newrelic,d.interaction=function(){return(new r).get()};var m=r.prototype={createTracer:function(t,e){var n={},r=this,o="function"==typeof e;return i(h+"tracer",[f.now(),t,n],r),function(){if(c.emit((o?"":"no-")+"fn-start",[f.now(),r,o],n),o)try{return e.apply(this,arguments)}catch(t){throw c.emit("fn-err",[arguments,this,t],n),t}finally{c.emit("fn-end",[f.now()],n)}}}};a("actionText,setName,setAttribute,save,ignore,onEnd,getContext,end,get".split(","),function(t,e){m[e]=o(h,e)}),newrelic.noticeError=function(t,e){"string"==typeof t&&(t=new Error(t)),u.recordSupportability("API/noticeError/called"),i("err",[t,f.now(),!1,e])}},{}],21:[function(t,e,n){function r(t){if(NREUM.init){for(var e=NREUM.init,n=t.split("."),r=0;r<n.length-1;r++)if(e=e[n[r]],"object"!=typeof e)return;return e=e[n[n.length-1]]}}e.exports={getConfiguration:r}},{}],22:[function(t,e,n){e.exports=function(t){if("string"==typeof t&&t.length)return t.length;if("object"==typeof t){if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if(!("undefined"!=typeof FormData&&t instanceof FormData))try{return JSON.stringify(t).length}catch(e){return}}}},{}],23:[function(t,e,n){var r=!1;try{var o=Object.defineProperty({},"passive",{get:function(){r=!0}});window.addEventListener("testPassive",null,o),window.removeEventListener("testPassive",null,o)}catch(i){}e.exports=function(t){return r?{passive:!0,capture:!!t}:!!t}},{}],24:[function(t,e,n){var r=0,o=navigator.userAgent.match(/Firefox[\/\s](\d+\.\d+)/);o&&(r=+o[1]),e.exports=r},{}],25:[function(t,e,n){function r(t,e){var n=[a,t,{name:t},e];return i("storeMetric",n,null,"api"),n}function o(t,e){var n=[s,t,{name:t},e];return i("storeEventMetrics",n,null,"api"),n}var i=t("handle"),a="sm",s="cm";e.exports={constants:{SUPPORTABILITY_METRIC:a,CUSTOM_METRIC:s},recordSupportability:r,recordCustom:o}},{}],26:[function(t,e,n){function r(){return s.exists&&performance.now?Math.round(performance.now()):(i=Math.max((new Date).getTime(),i))-a}function o(){return i}var i=(new Date).getTime(),a=i,s=t(34);e.exports=r,e.exports.offset=a,e.exports.getLastTimestamp=o},{}],27:[function(t,e,n){function r(t){return!(!t||!t.protocol||"file:"===t.protocol)}e.exports=r},{}],28:[function(t,e,n){function r(t,e){var n=t.getEntries();n.forEach(function(t){"first-paint"===t.name?p("timing",["fp",Math.floor(t.startTime)]):"first-contentful-paint"===t.name&&p("timing",["fcp",Math.floor(t.startTime)])})}function o(t,e){var n=t.getEntries();if(n.length>0){var r=n[n.length-1];if(c&&c<r.startTime)return;p("lcp",[r])}}function i(t){t.getEntries().forEach(function(t){t.hadRecentInput||p("cls",[t])})}function a(t){if(t instanceof v&&!g){var e=Math.round(t.timeStamp),n={type:t.type};e<=l.now()?n.fid=l.now()-e:e>l.offset&&e<=Date.now()?(e-=l.offset,n.fid=l.now()-e):e=l.now(),g=!0,p("timing",["fi",e,n])}}function s(t){"hidden"===t&&(c=l.now(),p("pageHide",[c]))}if(!("init"in NREUM&&"page_view_timing"in NREUM.init&&"enabled"in NREUM.init.page_view_timing&&NREUM.init.page_view_timing.enabled===!1)){var c,f,u,d,p=t("handle"),l=t("loader"),h=t(31),m=t(23),v=NREUM.o.EV;if("PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver){f=new PerformanceObserver(r);try{f.observe({entryTypes:["paint"]})}catch(w){}u=new PerformanceObserver(o);try{u.observe({entryTypes:["largest-contentful-paint"]})}catch(w){}d=new PerformanceObserver(i);try{d.observe({type:"layout-shift",buffered:!0})}catch(w){}}if("addEventListener"in document){var g=!1,y=["click","keydown","mousedown","pointerdown","touchstart"];y.forEach(function(t){document.addEventListener(t,a,m(!1))})}h(s)}},{}],29:[function(t,e,n){function r(){function t(){return e?15&e[n++]:16*Math.random()|0}var e=null,n=0,r=window.crypto||window.msCrypto;r&&r.getRandomValues&&(e=r.getRandomValues(new Uint8Array(31)));for(var o,i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx",a="",s=0;s<i.length;s++)o=i[s],"x"===o?a+=t().toString(16):"y"===o?(o=3&t()|8,a+=o.toString(16)):a+=o;return a}function o(){return a(16)}function i(){return a(32)}function a(t){function e(){return n?15&n[r++]:16*Math.random()|0}var n=null,r=0,o=window.crypto||window.msCrypto;o&&o.getRandomValues&&Uint8Array&&(n=o.getRandomValues(new Uint8Array(31)));for(var i=[],a=0;a<t;a++)i.push(e().toString(16));return i.join("")}e.exports={generateUuid:r,generateSpanId:o,generateTraceId:i}},{}],30:[function(t,e,n){function r(t,e){if(!o)return!1;if(t!==o)return!1;if(!e)return!0;if(!i)return!1;for(var n=i.split("."),r=e.split("."),a=0;a<r.length;a++)if(r[a]!==n[a])return!1;return!0}var o=null,i=null,a=/Version\/(\S+)\s+Safari/;if(navigator.userAgent){var s=navigator.userAgent,c=s.match(a);c&&s.indexOf("Chrome")===-1&&s.indexOf("Chromium")===-1&&(o="Safari",i=c[1])}e.exports={agent:o,version:i,match:r}},{}],31:[function(t,e,n){function r(t){function e(){t(s&&document[s]?document[s]:document[i]?"hidden":"visible")}"addEventListener"in document&&a&&document.addEventListener(a,e,o(!1))}var o=t(23);e.exports=r;var i,a,s;"undefined"!=typeof document.hidden?(i="hidden",a="visibilitychange",s="visibilityState"):"undefined"!=typeof document.msHidden?(i="msHidden",a="msvisibilitychange"):"undefined"!=typeof document.webkitHidden&&(i="webkitHidden",a="webkitvisibilitychange",s="webkitVisibilityState")},{}],32:[function(t,e,n){function r(t,e){var n=[],r="",i=0;for(r in t)o.call(t,r)&&(n[i]=e(r,t[r]),i+=1);return n}var o=Object.prototype.hasOwnProperty;e.exports=r},{}],33:[function(t,e,n){function r(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(o<0?0:o);++r<o;)i[r]=t[e+r];return i}e.exports=r},{}],34:[function(t,e,n){e.exports={exists:"undefined"!=typeof window.performance&&window.performance.timing&&"undefined"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(t,e,n){function r(){}function o(t){function e(t){return t&&t instanceof r?t:t?f(t,c,a):a()}function n(n,r,o,i,a){if(a!==!1&&(a=!0),!l.aborted||i){t&&a&&t(n,r,o);for(var s=e(o),c=m(n),f=c.length,u=0;u<f;u++)c[u].apply(s,r);var p=d[y[n]];return p&&p.push([x,n,r,s]),s}}function i(t,e){g[t]=m(t).concat(e)}function h(t,e){var n=g[t];if(n)for(var r=0;r<n.length;r++)n[r]===e&&n.splice(r,1)}function m(t){return g[t]||[]}function v(t){return p[t]=p[t]||o(n)}function w(t,e){l.aborted||u(t,function(t,n){e=e||"feature",y[n]=e,e in d||(d[e]=[])})}var g={},y={},x={on:i,addEventListener:i,removeEventListener:h,emit:n,get:v,listeners:m,context:e,buffer:w,abort:s,aborted:!1};return x}function i(t){return f(t,c,a)}function a(){return new r}function s(){(d.api||d.feature)&&(l.aborted=!0,d=l.backlog={})}var c="nr@context",f=t("gos"),u=t(32),d={},p={},l=e.exports=o();e.exports.getOrSetContext=i,l.backlog=d},{}],gos:[function(t,e,n){function r(t,e,n){if(o.call(t,e))return t[e];var r=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:r,writable:!0,enumerable:!1}),r}catch(i){}return t[e]=r,r}var o=Object.prototype.hasOwnProperty;e.exports=r},{}],handle:[function(t,e,n){function r(t,e,n,r){o.buffer([t],r),o.emit(t,e,n)}var o=t("ee").get("handle");e.exports=r,r.ee=o},{}],id:[function(t,e,n){function r(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:a(t,i,function(){return o++})}var o=1,i="nr@id",a=t("gos");e.exports=r},{}],loader:[function(t,e,n){function r(){if(!P++){var t=T.info=NREUM.info,e=v.getElementsByTagName("script")[0];if(setTimeout(f.abort,3e4),!(t&&t.licenseKey&&t.applicationID&&e))return f.abort();c(R,function(e,n){t[e]||(t[e]=n)});var n=a();s("mark",["onload",n+T.offset],null,"api"),s("timing",["load",n]);var r=v.createElement("script");0===t.agent.indexOf("http://")||0===t.agent.indexOf("https://")?r.src=t.agent:r.src=h+"://"+t.agent,e.parentNode.insertBefore(r,e)}}function o(){"complete"===v.readyState&&i()}function i(){s("mark",["domContent",a()+T.offset],null,"api")}var a=t(26),s=t("handle"),c=t(32),f=t("ee"),u=t(30),d=t(27),p=t(21),l=t(23),h=p.getConfiguration("ssl")===!1?"http":"https",m=window,v=m.document,w="addEventListener",g="attachEvent",y=m.XMLHttpRequest,x=y&&y.prototype,b=!d(m.location);NREUM.o={ST:setTimeout,SI:m.setImmediate,CT:clearTimeout,XHR:y,REQ:m.Request,EV:m.Event,PR:m.Promise,MO:m.MutationObserver};var E=""+location,R={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-spa-1212.min.js"},O=y&&x&&x[w]&&!/CriOS/.test(navigator.userAgent),T=e.exports={offset:a.getLastTimestamp(),now:a,origin:E,features:{},xhrWrappable:O,userAgent:u,disabled:b};if(!b){t(20),t(28),v[w]?(v[w]("DOMContentLoaded",i,l(!1)),m[w]("load",r,l(!1))):(v[g]("onreadystatechange",o),m[g]("onload",r)),s("mark",["firstbyte",a.getLastTimestamp()],null,"api");var P=0}},{}],"wrap-function":[function(t,e,n){function r(t,e){function n(e,n,r,c,f){function nrWrapper(){var i,a,u,p;try{a=this,i=d(arguments),u="function"==typeof r?r(i,a):r||{}}catch(l){o([l,"",[i,a,c],u],t)}s(n+"start",[i,a,c],u,f);try{return p=e.apply(a,i)}catch(h){throw s(n+"err",[i,a,h],u,f),h}finally{s(n+"end",[i,a,p],u,f)}}return a(e)?e:(n||(n=""),nrWrapper[p]=e,i(e,nrWrapper,t),nrWrapper)}function r(t,e,r,o,i){r||(r="");var s,c,f,u="-"===r.charAt(0);for(f=0;f<e.length;f++)c=e[f],s=t[c],a(s)||(t[c]=n(s,u?c+r:r,o,c,i))}function s(n,r,i,a){if(!h||e){var s=h;h=!0;try{t.emit(n,r,i,e,a)}catch(c){o([c,n,r,i],t)}h=s}}return t||(t=u),n.inPlace=r,n.flag=p,n}function o(t,e){e||(e=u);try{e.emit("internal-error",t)}catch(n){}}function i(t,e,n){if(Object.defineProperty&&Object.keys)try{var r=Object.keys(t);return r.forEach(function(n){Object.defineProperty(e,n,{get:function(){return t[n]},set:function(e){return t[n]=e,e}})}),e}catch(i){o([i],n)}for(var a in t)l.call(t,a)&&(e[a]=t[a]);return e}function a(t){return!(t&&t instanceof Function&&t.apply&&!t[p])}function s(t,e){var n=e(t);return n[p]=t,i(t,n,u),n}function c(t,e,n){var r=t[e];t[e]=s(r,n)}function f(){for(var t=arguments.length,e=new Array(t),n=0;n<t;++n)e[n]=arguments[n];return e}var u=t("ee"),d=t(33),p="nr@original",l=Object.prototype.hasOwnProperty,h=!1;e.exports=r,e.exports.wrapFunction=s,e.exports.wrapInPlace=c,e.exports.argsToArray=f},{}]},{},["loader",2,17,5,3,4]);
  ;NREUM.loader_config={accountID:"804283",trustKey:"804283",agentID:"402703674",licenseKey:"cf99e8d2a3",applicationID:"402703674"}
  ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"cf99e8d2a3",
    // Modified this value from the generated script, to pass prod vs dev
    applicationID: window.location.hostname.includes('journals.plos.org') ? "402703674" : "402694889",
    sa:1}
</script>
<!-- End New Relic -->






<header>
  <div id="topslot" class="head-top">

<div class="center">
<div class="title">Advertisement</div>
<!-- DoubleClick Ad Zone -->
  <div class='advertisement' id='div-gpt-ad-1458247671871-0' style='width:728px; height:90px;'>
    <script type='text/javascript'>
      googletag.cmd.push(function() { googletag.display('div-gpt-ad-1458247671871-0'); });
    </script>
  </div>
</div>
  </div>

  <div id="user" class="nav" data-user-management-url="https://community.plos.org">
  </div>
  <div id="pagehdr">

    <nav class="nav-main">




<h1 class="logo">
  <a href="/plosone/.">PLOS ONE</a>
</h1>

<section class="top-bar-section"> 

<ul class="nav-elements">


    <li class="multi-col-parent menu-section-header has-dropdown" id="publish">
    Publish
      <div class="dropdown mega ">
        <ul class="multi-col" id="publish-dropdown-list">

  <li class="menu-section-header " id="submissions">
    <span class="menu-section-header-title">  Submissions </span>

    <ul class="menu-section "
        id="submissions-dropdown-list">
      <li>
    <a href="/plosone/s/getting-started" >Getting Started</a>
  </li>

      <li>
    <a href="/plosone/s/submission-guidelines" >Submission Guidelines</a>
  </li>

      <li>
    <a href="/plosone/s/figures" >Figures</a>
  </li>

      <li>
    <a href="/plosone/s/tables" >Tables</a>
  </li>

      <li>
    <a href="/plosone/s/supporting-information" >Supporting Information</a>
  </li>

      <li>
    <a href="/plosone/s/latex" >LaTeX</a>
  </li>

      <li>
    <a href="/plosone/s/what-we-publish" >What We Publish</a>
  </li>

      <li>
    <a href="/plosone/s/preprints" >Preprints</a>
  </li>

      <li>
    <a href="/plosone/s/revising-your-manuscript" >Revising Your Manuscript</a>
  </li>

      <li>
    <a href="/plosone/s/submit-now" >Submit Now</a>
  </li>

      <li>
    <a href="https://collections.plos.org/s/calls-for-papers" >Calls for Papers</a>
  </li>

    </ul>

  </li>


  <li class="menu-section-header " id="policies">
    <span class="menu-section-header-title">  Policies </span>

    <ul class="menu-section "
        id="policies-dropdown-list">
      <li>
    <a href="/plosone/s/best-practices-in-research-reporting" >Best Practices in Research Reporting</a>
  </li>

      <li>
    <a href="/plosone/s/human-subjects-research" >Human Subjects Research</a>
  </li>

      <li>
    <a href="/plosone/s/animal-research" >Animal Research</a>
  </li>

      <li>
    <a href="/plosone/s/competing-interests" >Competing Interests</a>
  </li>

      <li>
    <a href="/plosone/s/disclosure-of-funding-sources" >Disclosure of Funding Sources</a>
  </li>

      <li>
    <a href="/plosone/s/licenses-and-copyright" >Licenses and Copyright</a>
  </li>

      <li>
    <a href="/plosone/s/data-availability" >Data Availability</a>
  </li>

      <li>
    <a href="/plosone/s/complementary-research" >Complementary Research</a>
  </li>

      <li>
    <a href="/plosone/s/materials-software-and-code-sharing" >Materials, Software and Code Sharing</a>
  </li>

      <li>
    <a href="/plosone/s/ethical-publishing-practice" >Ethical Publishing Practice</a>
  </li>

      <li>
    <a href="/plosone/s/authorship" >Authorship</a>
  </li>

      <li>
    <a href="/plosone/s/corrections-expressions-of-concern-and-retractions" >Corrections, Expressions of Concern, and Retractions</a>
  </li>

    </ul>

  </li>


  <li class="menu-section-header " id="manuscript-review-and-publication">
    <span class="menu-section-header-title">  Manuscript Review and Publication </span>

    <ul class="menu-section "
        id="manuscript-review-and-publication-dropdown-list">
      <li>
    <a href="/plosone/s/criteria-for-publication" >Criteria for Publication</a>
  </li>

      <li>
    <a href="/plosone/s/editorial-and-peer-review-process" >Editorial and Peer Review Process</a>
  </li>

      <li>
    <a href="https://plos.org/resources/editor-center" >Editor Center</a>
  </li>

      <li>
    <a href="/plosone/s/resources-for-editors" >Resources for Editors</a>
  </li>

      <li>
    <a href="/plosone/s/reviewer-guidelines" >Guidelines for Reviewers</a>
  </li>

      <li>
    <a href="/plosone/s/accepted-manuscripts" >Accepted Manuscripts</a>
  </li>

      <li>
    <a href="/plosone/s/comments" >Comments</a>
  </li>

    </ul>

  </li>
        </ul>
          <div class="calloutcontainer">



  <h3 class="callout-headline">Submit Your Manuscript</h3>

  <div class="action-contain">
  <p class="callout-content">
  Discover a faster, simpler path to publishing in a high-quality journal. <em>PLOS ONE</em> promises fair, rigorous peer review,
  broad scope, and wide readership – a perfect fit for your research every time.
  </p>

  <p class="button-contain special">
    <a class="button button-default" href="/plosone/static/publish">
     Learn More
    </a>
    <a class="button-link" href="https://www.editorialmanager.com/pone/default.asp">
      Submit Now
    </a>
  </p>
  </div>  <!-- opens in siteMenuCalloutDescription -->


          </div>
      </div>
    </li>



  <li class="menu-section-header has-dropdown " id="about">
    <span class="menu-section-header-title">  About </span>

    <ul class="menu-section dropdown "
        id="about-dropdown-list">
      <li>
    <a href="/plosone/static/publish" >Why Publish with PLOS ONE</a>
  </li>

      <li>
    <a href="/plosone/s/journal-information" >Journal Information</a>
  </li>

      <li>
    <a href="/plosone/s/staff-editors" >Staff Editors</a>
  </li>

      <li>
    <a href="/plosone/static/editorial-board" >Editorial Board</a>
  </li>

      <li>
    <a href="/plosone/s/section-editors" >Section Editors</a>
  </li>

      <li>
    <a href="/plosone/s/advisory-groups" >Advisory Groups</a>
  </li>

      <li>
    <a href="/plosone/s/find-and-read-articles" >Find and Read Articles</a>
  </li>

      <li>
    <a href="/plosone/s/publishing-information" >Publishing Information</a>
  </li>

      <li>
    <a href="https://plos.org/publication-fees" >Publication Fees</a>
  </li>

      <li>
    <a href="https://plos.org/press-and-media" >Press and Media</a>
  </li>

      <li>
    <a href="/plosone/s/contact" >Contact</a>
  </li>

    </ul>

  </li>

  <li data-js-tooltip-hover="trigger" class="subject-area menu-section-header">
  Browse
  </li>

<script src="/resource/js/vendor/jquery.hoverIntent.js" type="text/javascript"></script>
<script src="/resource/js/components/menu_drop.js" type="text/javascript"></script>
<script src="/resource/js/components/hover_delay.js" type="text/javascript"></script>
      <li id="navsearch" class="head-search">


    <form name="searchForm" action="/plosone/search" method="get">
      <fieldset>
        <legend>Search</legend>
        <label for="search">Search</label>
        <div class="search-contain">
          <input id="search" type="text" name="q" placeholder="SEARCH" required/>
          <button id="headerSearchButton" type="submit" aria-label="Submit search">
            <i title="Submit search" class="search-icon"></i>
          </button>
        </div>
      </fieldset>
      <input type="hidden" name="filterJournals" value="PLoSONE"/>
    </form>

    <a id="advSearch"
       href="/plosone/search">
      advanced search
    </a>




<script src="/resource/js/components/placeholder_style.js" type="text/javascript"></script>
      </li>

      </ul>     
      </section>  
    </nav>
  </div>

</header>
<section id="taxonomyContainer">

<script src="/resource/js/taxonomy-browser.js" type="text/javascript"></script>
<div id="taxonomy-browser" class="areas" data-search-url="/plosone/browse">
  <div class="wrapper">
    <div class="taxonomy-header">
      Browse Subject Areas
      <div id="subjInfo">?</div>
      <div id="subjInfoText">
        <p>Click through the PLOS taxonomy to find articles in your field.</p>
        <p>For more information about PLOS Subject Areas, click
          <a href="https://github.com/PLOS/plos-thesaurus/blob/master/README.md" target="_blank" title="Link opens in new window">here</a>.
        </p>
      </div>
    </div>
    <div class="levels">
      <div class="levels-container cf">
        <div class="levels-position"></div>
      </div>
      <a href="#" class="prev"></a>
      <a href="#" class="next active"></a>
    </div>
  </div>
  <div class="taxonomy-browser-border-bottom"></div>
</div>
</section>
<main> <div class="set-grid">

<header class="title-block">



<script src="/resource/js/components/signposts.js" type="text/javascript"></script>

<ul id="almSignposts" class="signposts">
  <li id="loadingMetrics">
    <p>Loading metrics</p>
  </li>
</ul>

<script type="text/template" id="signpostsGeneralErrorTemplate">
  <li id="metricsError">Article metrics are unavailable at this time. Please try again later.</li>
</script>

<script type="text/template" id="signpostsNewArticleErrorTemplate">
  <li></li><li></li><li id="tooSoon">Article metrics are unavailable for recently published articles.</li>
</script>

<script type="text/template" id="signpostsTemplate">
    <li id="almSaves">
      <%= s.numberFormat(saveCount, 0) %>
      <div class="tools" data-js-tooltip-hover="trigger">
        <a class="metric-term" href="/plosone/article/metrics?id=10.1371/journal.pone.0062170#savedHeader">Save</a>
        <p class="saves-tip" data-js-tooltip-hover="target"><a href="/plosone/article/metrics?id=10.1371/journal.pone.0062170#savedHeader">Total Mendeley and Citeulike bookmarks.</a></p>
      </div>
    </li>

    <li id="almCitations">
      <%= s.numberFormat(citationCount, 0) %>
      <div class="tools" data-js-tooltip-hover="trigger">
        <a class="metric-term" href="/plosone/article/metrics?id=10.1371/journal.pone.0062170#citedHeader">Citation</a>
        <p class="citations-tip" data-js-tooltip-hover="target"><a href="/plosone/article/metrics?id=10.1371/journal.pone.0062170#citedHeader">Paper's citation count computed by Dimensions.</a></p>
      </div>
    </li>

    <li id="almViews">
      <%= s.numberFormat(viewCount, 0) %>
      <div class="tools" data-js-tooltip-hover="trigger">
        <a class="metric-term" href="/plosone/article/metrics?id=10.1371/journal.pone.0062170#viewedHeader">View</a>
        <p class="views-tip" data-js-tooltip-hover="target"><a href="/plosone/article/metrics?id=10.1371/journal.pone.0062170#viewedHeader">PLOS views and downloads.</a></p>
      </div>
    </li>

    <li id="almShares">
      <%= s.numberFormat(shareCount, 0) %>
      <div class="tools" data-js-tooltip-hover="trigger">
        <a class="metric-term" href="/plosone/article/metrics?id=10.1371/journal.pone.0062170#discussedHeader">Share</a>
        <p class="shares-tip" data-js-tooltip-hover="target"><a href="/plosone/article/metrics?id=10.1371/journal.pone.0062170#discussedHeader">Sum of Facebook, Twitter, Reddit and Wikipedia activity.</a></p>
      </div>
    </li>
</script>

    <div class="article-meta">

<div class="classifications">
  <p class="license-short" id="licenseShort">Open Access</p>
  <p class="peer-reviewed" id="peerReviewed">Peer-reviewed</p>

<div class="article-type" >
  <p class="type-article" id="artType">Research Article</p>
</div>


</div>


    </div>
    <div class="article-title-etc">



<div class="title-authors">
  <h1 id="artTitle"><?xml version="1.0" encoding="UTF-8"?>miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells</h1>

<ul class="author-list clearfix"  data-js-tooltip="tooltip_container" id="author-list">



<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="0" class="author-name" >
Rounak Nassirpour,</a>    <div id="author-meta-0" class="author-info" data-js-tooltip="tooltip_target">

  
  
  <p id="authAffiliations-0"><span class="type">Affiliation</span>
    Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose0"> &#x02A2F; </a>
    </div>
</li>

<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="1" class="author-name" >
Pramod P. Mehta,</a>    <div id="author-meta-1" class="author-info" data-js-tooltip="tooltip_target">

  
  
  <p id="authAffiliations-1"><span class="type">Affiliation</span>
    Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose1"> &#x02A2F; </a>
    </div>
</li>

<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="2" class="author-name" >
Sangita M. Baxi,</a>    <div id="author-meta-2" class="author-info" data-js-tooltip="tooltip_target">

  
  
  <p id="authAffiliations-2"><span class="type">Affiliation</span>
    Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose2"> &#x02A2F; </a>
    </div>
</li>

<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="3" class="author-name" >
Min-Jean Yin <span class="email">  </span></a>    <div id="author-meta-3" class="author-info" data-js-tooltip="tooltip_target">

  
  <p id="authCorresponding-3"> <span class="email">* E-mail:</span> <a href="mailto:min-jean.yin@pfizer.com">min-jean.yin@pfizer.com</a></p>
  <p id="authAffiliations-3"><span class="type">Affiliation</span>
    Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose3"> &#x02A2F; </a>
    </div>
</li>

</ul>
<script src="/resource/js/components/tooltip.js" type="text/javascript"></script>

</div>


<div id="floatTitleTop" data-js-floater="title_author" class="float-title">
  <div class="set-grid">
    <div class="float-title-inner">
      <h1><?xml version="1.0" encoding="UTF-8"?>miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells</h1>

<ul id="floatAuthorList" data-js-floater="floated_authors">

  <li data-float-index="1">Rounak Nassirpour,&nbsp;

  </li>
  <li data-float-index="2">Pramod P. Mehta,&nbsp;

  </li>
  <li data-float-index="3">Sangita M. Baxi,&nbsp;

  </li>
  <li data-float-index="4">Min-Jean Yin

  </li>

</ul>



    </div>
    <div class="logo-close" id="titleTopCloser">
      <img src="/resource/img/logo-plos.png" style="height: 2em" alt="PLOS" />
      <div class="close-floater" title="close">x</div>
    </div>
  </div>
</div>

      <ul class="date-doi">
        <li id="artPubDate">Published: April 24, 2013</li>
        <li id="artDoi">
<a   href="https://doi.org/10.1371/journal.pone.0062170">https://doi.org/10.1371/journal.pone.0062170</a>
        </li>
        <li class="flex-spacer"></li>
      </ul>

    </div>
  <div>

  </div>
</header>
  <section class="article-body">



<ul class="article-tabs">

          <li class="tab-title active" id="tabArticle">
            <a href="/plosone/article?id=10.1371/journal.pone.0062170" class="article-tab-1">Article</a>
        </li>


              <li class="tab-title " id="tabAuthors">
            <a href="/plosone/article/authors?id=10.1371/journal.pone.0062170" class="article-tab-2">Authors</a>
        </li>


          <li class="tab-title " id="tabMetrics">
            <a href="/plosone/article/metrics?id=10.1371/journal.pone.0062170" class="article-tab-3">Metrics</a>
        </li>


          <li class="tab-title " id="tabComments">
            <a href="/plosone/article/comments?id=10.1371/journal.pone.0062170" class="article-tab-4">Comments</a>
        </li>

  <li class="tab-title" id="tabRelated">
    <a class="article-tab-5" id="tabRelated-link">Media Coverage</a> 
    <script>$(document).ready(function() { $.getMediaLink("10.1371/journal.pone.0062170").then(function (url) { $("#tabRelated-link").attr("href", url) } ) })</script>
  </li>
</ul>

    <div class="article-container">


<div id="nav-article">
  <ul class="nav-secondary">

    <li class="nav-comments" id="nav-comments">
      <a href="article/comments?id=10.1371/journal.pone.0062170">Reader Comments</a>
    </li>

    <li id="nav-figures"><a href="#" data-doi="10.1371/journal.pone.0062170">Figures</a></li>
  </ul>
</div>
<script src="/resource/js/components/scroll.js" type="text/javascript"></script>
<script src="/resource/js/components/nav_builder.js" type="text/javascript"></script>
<script src="/resource/js/components/floating_nav.js" type="text/javascript"></script>

<div id="figure-lightbox-container"></div>

<script id="figure-lightbox-template" type="text/template">
  <div id="figure-lightbox" class="reveal-modal full" data-reveal aria-hidden="true"
       role="dialog">
    <div class="lb-header">
      <h1 id="lb-title"><%= articleTitle %></h1>

      <div id="lb-authors">
            <span>Rounak Nassirpour</span>
            <span>Pramod P. Mehta</span>
            <span>Sangita M. Baxi</span>
            <span>Min-Jean Yin</span>
      </div>

      <div class="lb-close" title="close">&nbsp;</div>
    </div>
    <div class="img-container">
      <div class="loader"> <i class="fa-spinner"></i> </div>
      <img class="main-lightbox-image" src=""/>
      <aside id="figures-list">
        <% figureList.each(function (ix, figure) { %>
        <div class="change-img" data-doi="<%= figure.getAttribute('data-doi') %>">
          <img class="aside-figure" src="/plosone/article/figure/image?size=inline&id=<%= figure.getAttribute('data-doi') %>" />
        </div>
        <% }) %>
        <div class="dummy-figure">
        </div>
      </aside>
    </div>
    <div id="lightbox-footer">

      <div id="btns-container" class="lightbox-row <% if(figureList.length <= 1) { print('one-figure-only') } %>">
        <div class="fig-btns-container reset-zoom-wrapper left">
          <span class="fig-btn reset-zoom-btn">Reset zoom</span>
        </div>
        <div class="zoom-slider-container">
          <div class="range-slider-container">
            <span id="lb-zoom-min"></span>
            <div class="range-slider round" data-slider data-options="start: 20; end: 200; initial: 20;">
              <span class="range-slider-handle" role="slider" tabindex="0"></span>
              <span class="range-slider-active-segment"></span>
              <input type="hidden">
            </div>
            <span id="lb-zoom-max"></span>
          </div>
        </div>
        <% if(figureList.length > 1) { %>
        <div class="fig-btns-container">
          <span class="fig-btn all-fig-btn"><i class="icon icon-all"></i> All Figures</span>
          <span class="fig-btn next-fig-btn"><i class="icon icon-next"></i> Next</span>
          <span class="fig-btn prev-fig-btn"><i class="icon icon-prev"></i> Previous</span>
        </div>
        <% } %>
      </div>
      <div id="image-context">
      </div>
    </div>
  </div>
</script>

<script id="image-context-template" type="text/template">
  <div class="footer-text">
    <div id="figure-description-wrapper">
      <div id="view-more-wrapper" style="<% descriptionExpanded? print('display:none;') : '' %>">
        <span id="figure-title"><%= title %></span>
        <p id="figure-description">
          <%= description %>&nbsp;&nbsp;
        </p>
        <span id="view-more">show more<i class="icon-arrow-right"></i></span>

      </div>
      <div id="view-less-wrapper" style="<% descriptionExpanded? print('display:inline-block;') : '' %>" >
        <span id="figure-title"><%= title %></span>
        <p id="full-figure-description">
          <%= description %>&nbsp;&nbsp;
          <span id="view-less">show less<i class="icon-arrow-left"></i></span>
        </p>
      </div>
    </div>
  </div>
  <div id="show-context-container">
    <a class="btn show-context" href="<%= showInContext(strippedDoi) %>">Show in Context</a>
  </div>
  <div id="download-buttons">
    <h3>Download:</h3>
    <div class="item">
      <a href="/plosone/article/figure/image?size=original&download=&id=<%= doi %>" title="original image">
        <span class="download-btn">TIFF</span>
      </a>
      <span class="file-size"><%= fileSizes.original %></span>
    </div>
    <div class="item">
      <a href="/plosone/article/figure/image?size=large&download=&id=<%= doi %>" title="large image">
        <span class="download-btn">PNG</span>
      </a>
      <span class="file-size"><%= fileSizes.large %></span>
    </div>
    <div class="item">
      <a href="/plosone/article/figure/powerpoint?id=<%= doi %>" title="PowerPoint slide">
        <span class="download-btn">PPT</span>
      </a>
    </div>

  </div>
</script>
      <div class="article-content">




  <div class="amendment amendment-retraction toc-section">
  <a data-toc="amendment-0" title="Retraction" id="amendment-0" name="amendment-0"></a>

  <h2>Retraction</h2>
      <div class="amendment-body">
        <a xmlns:plos="http://plos.org" id="body1.p1" name="body1.p1" class="link-target"></a><p xmlns:plos="http://plos.org">The authors Min-Jean Yin and Rounak Nassirpour and a Pfizer representative contacted the editorial office to raise that there are image duplications in Figure 4B of this article. Pfizer has undertaken a review and deemed that important conclusions in the manuscript cannot be verified, as original images cannot be located.</p>
<a xmlns:plos="http://plos.org" id="body1.p2" name="body1.p2" class="link-target"></a><p xmlns:plos="http://plos.org">In light of the concerns identified, the authors and the <em>PLOS ONE</em> Editors retract this article. We did not receive any response or comment from Pramod Mehta.</p>

      </div>
    <div class="amendment-citation">
      <p>
          <span class="amendment-date">
            10 Apr 2017:
          </span>


The PLOS ONE Editors


  (2017)

    <?xml version="1.0" encoding="UTF-8"?>Retraction: miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells.

PLOS ONE  12(4): e0175869.

<a   href="https://doi.org/10.1371/journal.pone.0175869">https://doi.org/10.1371/journal.pone.0175869</a>


            <span class="link-separator"> </span>
            <a href="/plosone/article?id=10.1371/journal.pone.0175869" class="amendment-link">
              View 
  retraction

            </a>
      </p>
    </div>
  </div>


<div id="figure-carousel-section">
  <h2>Figures</h2>

  <div id="figure-carousel">

    <div class="carousel-wrapper">
      <div class="slider">

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0062170.g001">

                <img src="/plosone/article/figure/image?size=inline&amp;id=10.1371/journal.pone.0062170.g001"
                     loading="lazy"
                     alt="Figure 1"
                />

            </div>

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0062170.g002">

                <img src="/plosone/article/figure/image?size=inline&amp;id=10.1371/journal.pone.0062170.g002"
                     loading="lazy"
                     alt="Figure 2"
                />

            </div>

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0062170.g003">

                <img src="/plosone/article/figure/image?size=inline&amp;id=10.1371/journal.pone.0062170.g003"
                     loading="lazy"
                     alt="Figure 3"
                />

            </div>

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0062170.g004">

                <img src="/plosone/article/figure/image?size=inline&amp;id=10.1371/journal.pone.0062170.g004"
                     loading="lazy"
                     alt="Figure 4"
                />

            </div>

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0062170.g005">

                <img src="/plosone/article/figure/image?size=inline&amp;id=10.1371/journal.pone.0062170.g005"
                     loading="lazy"
                     alt="Figure 5"
                />

            </div>
      </div>
    </div>

    <div class="carousel-control">
      <span class="button previous"></span>
      <span class="button next"></span>
    </div>
    <div class="carousel-page-buttons">

    </div>
  </div>
</div>
<script src="/resource/js/vendor/jquery.touchswipe.js" type="text/javascript"></script>
<script src="/resource/js/components/figure_carousel.js" type="text/javascript"></script>
<script src="/resource/js/vendor/jquery.dotdotdot.js" type="text/javascript"></script>


        <div class="article-text" id="artText">
          



<div xmlns:plos="http://plos.org" class="abstract toc-section abstract-type-"><a id="abstract0" name="abstract0" data-toc="abstract0" class="link-target" title="Abstract"></a><h2>Abstract</h2><div class="abstract-content">
<div id="section1" class="section toc-section">

<a id="article1.front1.article-meta1.abstract1.sec1.p1" name="article1.front1.article-meta1.abstract1.sec1.p1" class="link-target"></a><p>Patients with triple-negative breast cancers (TNBCs) typically have a poor prognosis. TNBCs are characterized by their resistance to apoptosis, aggressive cellular proliferation, migration and invasion, and currently lack molecular markers and effective targeted therapy. Recently, miR-221/miR-222 have been shown to regulate ERα expression and ERα-mediated signaling in luminal breast cancer cells, and also to promote EMT in TNBCs. In this study, we characterized the role of miR-221 in a panel of TNBCs as compared to other breast cancer types. miR-221 knockdown not only blocked cell cycle progression, induced cell apoptosis, and inhibited cell proliferation <em>in-vitro</em> but it also inhibited <em>in-vivo</em> tumor growth by targeting p27<sup>kip1</sup>. Furthermore, miR-221 knockdown inhibited cell migration and invasion by altering E-cadherin expression, and its regulatory transcription factors Snail and Slug in human TNBC cell lines. Therefore, miR-221 functions as an oncogene and is essential in regulating tumorigenesis in TNBCs both <em>in vitro</em> as well as <em>in vivo.</em></p>
</div>
</div></div>


<div xmlns:plos="http://plos.org" class="articleinfo"><p><strong>Citation: </strong>Nassirpour R, Mehta PP, Baxi SM, Yin M-J (2013) miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells. PLoS ONE 8(4):
           e62170.
        
        https://doi.org/10.1371/journal.pone.0062170</p><p><strong>Editor: </strong>Aamir Ahmad, Wayne State University School of Medicine, United States of America</p><p><strong>Received: </strong>November 20, 2012; <strong>Accepted: </strong>March 18, 2013; <strong>Published: </strong> April 24, 2013</p><p><strong>Copyright: </strong> © 2013 Nassirpour et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p><p><strong>Funding: </strong>The authors have no support or funding to report.</p><p><strong>Competing interests: </strong> All authors are current full-time employees of Pfizer Inc. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.</p></div>





<div xmlns:plos="http://plos.org" id="section1" class="section toc-section"><a id="s1" name="s1" data-toc="s1" class="link-target" title="Introduction"></a><h2>Introduction</h2><a id="article1.body1.sec1.p1" name="article1.body1.sec1.p1" class="link-target"></a><p>microRNAs (miRNAs) are non-coding, single-stranded ∼22 nucleotides long small RNAs that act as agents of the RNA interference pathway and negatively regulate the translation by either cleaving or degrading their targeted transcripts <a href="#pone.0062170-Bartel1" class="ref-tip">[1]</a>. Because miRNAs usually bind to their targets with incomplete complementarity, a single miRNA can potentially regulate the translation of multiple target genes involved in various cellular processes <a href="#pone.0062170-Lim1" class="ref-tip">[2]</a>, <a href="#pone.0062170-Lewis1" class="ref-tip">[3]</a>. In fact, miRNAs have been implicated in the regulation of a variety of biological functions, including cellular proliferation, differentiation, and apoptosis <a href="#pone.0062170-EsquelaKerscher1" class="ref-tip">[4]</a>, <a href="#pone.0062170-Ambros1" class="ref-tip">[5]</a>. Growing evidence indicates that miRNAs can function as tumor suppressors or oncogenes <a href="#pone.0062170-EsquelaKerscher1" class="ref-tip">[4]</a>, and miRNA expression profiling analyses have revealed characteristic miRNA signatures in a variety of human cancers <a href="#pone.0062170-Calin1" class="ref-tip">[6]</a>, <a href="#pone.0062170-Lu1" class="ref-tip">[7]</a>. Furthermore, miRNAs are frequently located at fragile genomic regions susceptible to amplification, deletion, or translocation during tumor development <a href="#pone.0062170-Calin2" class="ref-tip">[8]</a>. Since miRNAs are believed to be pivotal players in tumor development, investigations of differential expression of miRNAs and their corresponding targets might prove to be instrumental for the diagnosis and treatment of various cancers.</p>
<a id="article1.body1.sec1.p2" name="article1.body1.sec1.p2" class="link-target"></a><p>Molecular profiling has allowed us to classify breast cancers to five subtypes based on their distinctive gene expression signatures <a href="#pone.0062170-Perou1" class="ref-tip">[9]</a>. The five subtypes are luminal A, luminal B, Human Epidermal Growth Factor Receptor 2 (HER2) positive, basal-like, and normal-like breast cancers. Basal-like tumors are characterized by the expression of genes specific for basal epithelial cell proliferation, inhibition of apoptotic pathways, and aggressive migration and invasion <a href="#pone.0062170-Perou1" class="ref-tip">[9]</a>–<a href="#pone.0062170-Kang1" class="ref-tip">[11]</a>. Basal-like breast cancers (BLBCs) are often stained negative by immunochemistry for estrogen receptor (ER), progesterone receptor (PR), and HER2 and thus are called triple negative breast cancers (TNBCs). Although BLBC and TNBC share numerous clinical and pathological features, they are not identical <a href="#pone.0062170-Bidard1" class="ref-tip">[12]</a>, <a href="#pone.0062170-Rakha1" class="ref-tip">[13]</a>. In the majority of cases, however, these two categories share similar clinical characteristics, prognosis and treatment options and thus, the term “TNBC” will be used in this study to collectively describe BLBC and TNBC cell lines and patient populations. Clinical studies have shown that TNBCs are the most aggressive breast cancer type and TNBC patients are frequently faced with poor prognosis and high mortality <a href="#pone.0062170-Carey1" class="ref-tip">[14]</a>, <a href="#pone.0062170-Dent1" class="ref-tip">[15]</a>. Thus, the development of targeted therapies for TNBCs is urgently and critically needed for this patient population.</p>
<a id="article1.body1.sec1.p3" name="article1.body1.sec1.p3" class="link-target"></a><p>miR-221 and miR-222 are encoded in tandem from a gene cluster located on chromosome X and have been shown to be up-regulated in a panoply of cancer types. Due to their seed sequence similarity, both miRNAs have been shown to directly target p27<sup>kip1</sup>, Bmf, PTEN, Mdm2, PUMA, and TRPS1 <a href="#pone.0062170-Gramantieri1" class="ref-tip">[16]</a>–<a href="#pone.0062170-Stinson1" class="ref-tip">[22]</a>. In breast cancer, miR-221/miR-222 have been shown to be involved in regulation of ERα expression, suppression of ERα-mediated signaling, as well as drug resistance mechanisms <a href="#pone.0062170-Zhao1" class="ref-tip">[23]</a>–<a href="#pone.0062170-Cochrane1" class="ref-tip">[27]</a>. More recently miR-221/miR-222 have been shown to be over-expressed in triple-negative primary breast cancers or cell lines <a href="#pone.0062170-Radojicic1" class="ref-tip">[28]</a>–<a href="#pone.0062170-Lambertini1" class="ref-tip">[30]</a>. In this study, we investigated the molecular mechanisms of cellular transformation regulated by miR-221/222 specifically in a panel of human TNBC cell lines compared to other breast cancer types and validated our findings <em>in vivo</em>. We show that miR-221 is an oncogene and modulates cell proliferation and tumor progression via targeting p27<sup>kip1</sup> and EMT transition in TNBCs both <em>in vitro</em> as well as <em>in vivo</em>.</p>
</div>

<div xmlns:plos="http://plos.org" id="section2" class="section toc-section"><a id="s2" name="s2" data-toc="s2" class="link-target" title="Materials and Methods"></a><h2>Materials and Methods</h2>
<div id="section1" class="section toc-section"><a id="s2a" name="s2a" class="link-target" title="Cell Culture"></a>
<h3>Cell Culture</h3>
<a id="article1.body1.sec2.sec1.p1" name="article1.body1.sec2.sec1.p1" class="link-target"></a><p>All cell lines were obtained from the American Type Culture Collection and maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) supplemented with L-glutamine and grown in a humidified atmosphere of 5% CO<sub>2</sub> in air at 37°C.</p>
</div>

<div id="section2" class="section toc-section"><a id="s2b" name="s2b" class="link-target" title="Stable Cell Line Generation"></a>
<h3>Stable Cell Line Generation</h3>
<a id="article1.body1.sec2.sec2.p1" name="article1.body1.sec2.sec2.p1" class="link-target"></a><p>System Bioscience’s miRZip™ anti-sense miRNAs are stably expressed RNAi hairpins that inhibit miRNA activity. The miRZip shRNAs produce short, single-stranded anti-miRNAs that competitively bind their endogenous miRNA target and inhibit its function. The miRZip short hairpin RNAs are cloned into SBI’s pGreenPuro™ shRNA expression vector, an improved third generation HIV-based expression lentivector. The lentiviral vector contains the genetic elements responsible for packaging, transduction, and stable integration of the viral construct into genomic DNA, inducing expression of the anti-miRNA effector sequence. For production of a high titer of viral particles, we used the ViraPower™ Lentiviral Support Kit (Invitrogen) employing Lipofectamine™ 2000 (Invitrogen) for transfecting the miRzip vectors into HEK-293T cells. Because infected cells stably express cop-GFP and puromycin, as well as the anti-miRNA cloned into the miRZip™ vector, we successfully used puromycin to select for the infected cells harboring the miRzip.</p>
</div>

<div id="section3" class="section toc-section"><a id="s2c" name="s2c" class="link-target" title="RT-PCR"></a>
<h3>RT-PCR</h3>
<a id="article1.body1.sec2.sec3.p1" name="article1.body1.sec2.sec3.p1" class="link-target"></a><p>TaqMan miRNA assays (Life Technologies, CA) were used to quantify the expression levels of mature miR-221 and miR-222 as well mRNAs p27, Snail, Slug, vimentin and E-Cadherin. Total RNA extracted by mirVana (Life Technologies) was reverse transcribed in a reaction mixture containing miR-specific stem-loop RT primers. Quantitative polymerase chain reaction (qPCR) was performed in triplicate with reactions containing amplified cDNA and TaqMan primers in Universal Master Mix without AmpErase UNG (Applied Biosystems). The qPCR was conducted at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds in 7900 HT Real Time PCR system (Applied Biosystems) and threshold cycles (<em>C</em><sub>T</sub>) were calculated using Sequence Detection Software (SDS v2.2.1, Applied Biosystems). All mRNA quantification data were normalized to GAPDH. All miRNA data are expressed relative to a RNU48 small nuclear (sn) RNA TaqMan PCR performed on the same samples, unless otherwise specified. Fold expression was calculated from the triplicate of <em>C</em><sub>T</sub> values following the 2<sup>−ΔΔCt</sup> method.</p>
</div>

<div id="section4" class="section toc-section"><a id="s2d" name="s2d" class="link-target" title="Immunoblotting"></a>
<h3>Immunoblotting</h3>
<a id="article1.body1.sec2.sec4.p1" name="article1.body1.sec2.sec4.p1" class="link-target"></a><p>Cells were lysed in buffer composed of 150 mM NaCl, 1.5 mM MgCl<sub>2</sub>, 50 mM HEPES, 10% glycerol, 1 mM EGTA, 1% Triton X-100, 0.5% NP-40 supplemented with 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mM PMSF, 1 mM NaF, 1 mM β-glycerophosphate, protease inhibitor cocktail (Roche), and phosphatase inhibitor cocktail (Roche) added prior to use. Protein concentration was determined using the BCA Protein Assay (Pierce/Thermo Fisher Scientific) per manufacturer’s instructions. Protein (30–50 µg) was resolved by SDS-PAGE and transferred onto nitrocellulose membrane. Blots were probed with primary antibodies to detect proteins of interest. After incubation with secondary antibodies, membranes were visualized by chemiluminescence (Pierce/Thermo Fisher Scientific). All antibodies were purchased from Cell Signaling Technology, with the exception of GAPDH (Santa Cruz Biotechnology).</p>
</div>

<div id="section5" class="section toc-section"><a id="s2e" name="s2e" class="link-target" title="Cell Proliferation, Apoptosis Assay, Migration, and Invasion Assays"></a>
<h3>Cell Proliferation, Apoptosis Assay, Migration, and Invasion Assays</h3>
<a id="article1.body1.sec2.sec5.p1" name="article1.body1.sec2.sec5.p1" class="link-target"></a><p>Resazurin Fluorescent Assay was used for the proliferation studies. Briefly, Cells were seeded at 3000–5,000 cells/100ul/well in DMEM +10% FBS in a 96 well plate, and incubated overnight at 37°C in 5% CO<sub>2</sub>. Resazurin (Sigma) fluorescent dye was added (1∶100) to each well. The cells were incubated at 37°C in 5% CO<sub>2</sub> for 4 hours at which point the plate was read for fluorescence at 530/590 nm on the HTS 7000 plate reader. Cell Signaling Technologies PathScan® Apoptosis Multi-Target Sandwich ELISA Kits were used in the apoptosis assays. Briefly, antibodies for cleaved caspase 3 and phosphorylated BAD had been coated onto microwells. After incubation with the cell lysates, the target protein was captured by the coated antibody. Following extensive washing, a detection antibody was added to detect the captured target protein. An HRP-linked secondary antibody was then used to recognize the bound detection antibody. HRP substrate, TMB, was added for color development which was measured to quantity the level of bound target protein. Cell Biolab’s CytoSelect™ Cell Migration Assay Kit containing polycarbonate membrane inserts (8 µm pore size) in a 24-well plate was used in our migration assays. Migratory cells were able to extend protrusions towards FBS (used as the chemo-attractant), and pass through the pores of the polycarbonate membrane. The non-migratory cells were removed from the top of the membrane and the migratory cells were stained and quantified. Similarly, Cell Biolabs CytoSelect™ Cell Invasion Assay Kit containing basement membrane-coated inserts were used to assay the invasive properties of the cells. The upper surface of the insert membrane is coated with a uniform layer of dried basement membrane matrix solution. This basement membrane layer serves as a barrier to discriminate invasive cells from non-invasive cells. The non-invasive cells were removed from the top of the membrane and the invading cells were stained and quantified.</p>
</div>

<div id="section6" class="section toc-section"><a id="s2f" name="s2f" class="link-target" title="Cell Cycle Analysis"></a>
<h3>Cell Cycle Analysis</h3>
<a id="article1.body1.sec2.sec6.p1" name="article1.body1.sec2.sec6.p1" class="link-target"></a><p>MDA-MB-231, BT-20, and MDA-MB-468 parental cells and cells stably expressing miR-221-ZIP, or scramble miRNA-ZIP were cultured to 70–90% confluency and allowed to adhere overnight. Cells were collected, fixed, and permeabilized using the Cell Cycle Phase Determination Kit (Cayman Chemical) following the manufacturer’s protocol. Samples were stored at −20°C until DNA stained with propidium iodide and read on a BD FACSCalibur (BD Biosciences). Data analysis was done with FCS Express (De Novo Software). All experiments were repeated at least 3 times and representative data set is shown.</p>
</div>

<div id="section7" class="section toc-section"><a id="s2g" name="s2g" class="link-target" title="Animal Studies"></a>
<h3>Animal Studies</h3>
<a id="article1.body1.sec2.sec7.p1" name="article1.body1.sec2.sec7.p1" class="link-target"></a><p>Six- to eight-week-old nu/nu athymic female mice were obtained from Jackson Labs. The mice were maintained in pressurized ventilated caging at the Pfizer La Jolla animal facility. All animal studies were done under the ethical approval by Pfizer Institutional Animal Care and Use Committees. Tumors were established by injecting 5×10<sup>6</sup> cells suspended 1∶1 (v/v) with reconstituted basement membrane (Matrigel, BD Biosciences). Tumor dimensions were measured with Vernier calipers, and tumor volumes were calculated using this formula: π/6×(larger diameter)×(smaller diameter)<sup>2</sup>. Tumor growth inhibition percentage (TGI %) was calculated as 100×(1−ΔT/ΔC). One way ANOVA Statistical analysis were performed and noted as *** depicting p-value less than or equal to 0.001.</p>
</div>
</div>

<div xmlns:plos="http://plos.org" id="section3" class="section toc-section"><a id="s3" name="s3" data-toc="s3" class="link-target" title="Results"></a><h2>Results</h2>
<div id="section1" class="section toc-section"><a id="s3a" name="s3a" class="link-target" title="miR-221 is Specifically Up-regulated in Human TNBC Cell Lines"></a>
<h3>miR-221 is Specifically Up-regulated in Human TNBC Cell Lines</h3>
<a id="article1.body1.sec3.sec1.p1" name="article1.body1.sec3.sec1.p1" class="link-target"></a><p>The expression level of miR-221 and miR-222 were examined by qRT-PCR in 4 TNBC lines: MDA-MB-231, Hs-578T, BT-20, and MDA-MB-468; 2 HER2 positive lines: SKBR3 and MDA-MB-361; and 3 ER positive lines: T47D, ZR75–1, and MCF-7. In comparison to the expression level in normal breast tissue (RNA acquired from Applied Biosystems), miR-221 is up-regulated in all the TNBC lines while down-regulated in the non-TNBC lines (<a href="#pone-0062170-g001">Figure 1A</a>). Surprisingly, although clustered with miR-221, the expression level of miR-222 is only up-regulated mildly (1–1.5 fold) in Hs-578-T and BT-20 (compared to normal breast tissue), but down regulated in MDA-MB-468 and the other non-TNBC lines tested (<a href="#pone-0062170-g001">Figure 1B</a>). These results indicate that although miR-221/miR-222 are both down-regulated in non-TNBC cells, miR-221 is specifically over-expressed in the TNBC cell lines in comparison to normal breast tissue. Therefore, over-expression of miR-221 may be important in maintaining the characteristics of triple negative breast cancer cells.</p>
<a class="link-target" id="pone-0062170-g001" name="pone-0062170-g001"></a><div class="figure" data-doi="10.1371/journal.pone.0062170.g001"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=10.1371/journal.pone.0062170.g001" data-doi="10.1371/journal.pone.0062170" data-uri="10.1371/journal.pone.0062170.g001"><img src="article/figure/image?size=inline&amp;id=10.1371/journal.pone.0062170.g001" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pone.0062170.g001"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&amp;size=large&amp;id=10.1371/journal.pone.0062170.g001"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&amp;size=original&amp;id=10.1371/journal.pone.0062170.g001"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Figure 1. </span> miR-221 is over expressed in TNBCs.</div><p class="caption_target"><a id="article1.body1.sec3.sec1.fig1.caption1.p1" name="article1.body1.sec3.sec1.fig1.caption1.p1" class="link-target"></a><p>qRT-PCR was performed to quantitatively measure RNA expression levels of miR-221 (A) and miR-222 (B) in a panel of breast cancer cell lines. All expression levels are displayed as fold changes normalized to the expression level in normal breast tissue.</p>
</p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0062170.g001">
              https://doi.org/10.1371/journal.pone.0062170.g001</a></p></div></div>

<div id="section2" class="section toc-section"><a id="s3b" name="s3b" class="link-target" title="miR-221 Targets p27kip1 to Regulate Cell Cycle Progression in TNBCs"></a>
<h3>miR-221 Targets p27<sup>kip1</sup> to Regulate Cell Cycle Progression in TNBCs</h3>
<a id="article1.body1.sec3.sec2.p1" name="article1.body1.sec3.sec2.p1" class="link-target"></a><p>p27<sup>kip1</sup>, an inhibitor of cyclin dependent kinase involved in the regulation of the cell cycle, has previously been shown to be a potential target of miR-221 in a variety of cancers <a href="#pone.0062170-Galardi1" class="ref-tip">[17]</a>, <a href="#pone.0062170-Miller1" class="ref-tip">[24]</a>, <a href="#pone.0062170-leSage1" class="ref-tip">[31]</a>, <a href="#pone.0062170-Fornari1" class="ref-tip">[32]</a>. Since highly activated cell proliferation is one of the major characteristics of TNBCs, we investigated whether miR-221 also targets p27<sup>kip1</sup>in this particular breast cancer subtype. If so, we would expect an inverse relationship between the miR-221 and p27 levels. We thus measured the expression level of p27 in a variety of breast cancer cell lines as shown in <a href="#pone-0062170-g002">Figure 2A</a>. As expected, p27 is expressed at much lower levels in TNBCs than in other types of breast cancer cell lines. In fact, p27 expression level was inversely correlated to miR-221 expression level in most the breast cancer cell lines tested as shown in <a href="#pone-0062170-g001">Figure 1A</a> and <a href="#pone-0062170-g002">Figure 2A</a>. Since miR-221 and miR-222 are highly homologous and contain identical seed sequences, one might expect them to regulate the same target genes and play similar biological functions in cancer cells <a href="#pone.0062170-Galardi1" class="ref-tip">[17]</a>. However, the relative expression level of miR-221 versus normal breast tissue is higher in the comparison to miR-222, and since miR-221, but not miR-222, was specifically over expressed in the TNBCs tested, we focused our experiments on miR-221. Next, we successfully and stably knocked down miR-221 using a miR-ZIP lentiviral vector in various breast cancer cells, as shown in <a href="#pone-0062170-g002">Figure 2B</a>. Briefly, miRZip are short, single-stranded anti-miRNAs in a lentivirus backbone that can be stably expressed to specifically target miRNAs of interest and alter translation. Knockdown of miR-221 in MDA-MB-231, BT-20, and MDA-MB-468 TNBC cell lines induced significant increases of p27<sup>kip1</sup> both in mRNA expression and protein levels as shown in <a href="#pone-0062170-g002">Figure 2C</a> and <a href="#pone-0062170-g002">Figure 2D</a>, confirming that p27<sup>kip1</sup> is a target of this miRNA in TNBCs. Since p27<sup>kip1</sup> is involved in cell cycle regulation by modulating cyclin-dependent kinase (CDK) activity <a href="#pone.0062170-Lu3" class="ref-tip">[33]</a>, we also investigated the effects of miR-221 inhibition on cell cycle progression in TNBC cell lines. miR-221 knockdown induced a G1 arrest as evidenced by observing a higher number of cells in G1 phase compared to S phase (as shown in <a href="#pone-0062170-g002">Figure 2E</a>). Furthermore, cell cycle profile analysis demonstrated that miR-221 knockdown in MDA-MB-231, BT-20, and MDA-MB-468 cells exhibited higher sub-G1 cell population, again suggesting that miR-221 knockdown restored p27<sup>kip1</sup> levels and subsequently induced apoptosis probably by blocking the aggressive cell cycle progression in these TNBC cell lines.</p>
<a class="link-target" id="pone-0062170-g002" name="pone-0062170-g002"></a><div class="figure" data-doi="10.1371/journal.pone.0062170.g002"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=10.1371/journal.pone.0062170.g002" data-doi="10.1371/journal.pone.0062170" data-uri="10.1371/journal.pone.0062170.g002"><img src="article/figure/image?size=inline&amp;id=10.1371/journal.pone.0062170.g002" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pone.0062170.g002"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&amp;size=large&amp;id=10.1371/journal.pone.0062170.g002"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&amp;size=original&amp;id=10.1371/journal.pone.0062170.g002"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Figure 2. </span> miR-221 modulates cell cycle progression by targeting p27<sup>kip1</sup>.</div><p class="caption_target"><a id="article1.body1.sec3.sec2.fig1.caption1.p1" name="article1.body1.sec3.sec2.fig1.caption1.p1" class="link-target"></a><p>(A) mRNA expression level of p27<sup>kip1</sup> was measured in a panel of breast cancer cell lines. Data are displayed as fold changes normalized to the expression level in normal breast tissue. (B) TNBC lines, MDA-MB-231, BT-20, and MDA-MB-468 cells were established to stably express anti-miR-221 (miR-221-ZIP) or a control scramble miRNA (Scramble-ZIP). miR-221 expression level was measured and is displayed as fold changes normalized to the expression level of parental cell lines. (C) Transcript expression level of p27<sup>kip1</sup> was measured and is displayed as fold changes normalized to the expression level of parental cell lines. (D) Western blot analysis of MDA-MB-231, BT-20, and MDA-MB-468 cells stably expressing anti-miR-221 or scramble miR-ZIP depicting changes in p27 protein level. GAPDH was used as loading control. (E) MDA-MB-231, BT-20, and MDA-MB-468 cells stably expressing anti-miR-221 or scramble miR-ZIP were cultured for 72 hours to reach 80–90% confluency before harvesting and cell cycle analysis was performed and displayed as percentages of each cell cycle stage. These experiments were repeated at least three times, and representative data is shown.</p>
</p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0062170.g002">
              https://doi.org/10.1371/journal.pone.0062170.g002</a></p></div></div>

<div id="section3" class="section toc-section"><a id="s3c" name="s3c" class="link-target" title="Down Regulation of miR-221 in TNBCs Inhibits Cell Proliferation and Tumor Growth in Mice"></a>
<h3>Down Regulation of miR-221 in TNBCs Inhibits Cell Proliferation and Tumor Growth in Mice</h3>
<a id="article1.body1.sec3.sec3.p1" name="article1.body1.sec3.sec3.p1" class="link-target"></a><p>Since cell cycle analysis demonstrated that miR-221 knockdown was able to block cell cycle progression and induce higher sub-G1 cell population, we next investigated whether miR-221 knockdown also induced apoptosis by direct measurement of apoptosis markers: cleaved caspase 3 and BAD phosphorylation (pBAD). As shown in <a href="#pone-0062170-g003">Figure 3A</a>, down regulation of miR-221 induced significantly higher levels of cleaved caspase 3 in MDA-MB-231 and BT-20 cells, and slightly higher levels of cleaved caspase 3 in MDA-MB-468 cells. Knocking down miR-221, however, did decrease phosphorylation of Bcl-2-associated death promoter (<em>BAD</em>), a pro-apoptotic member of the Bcl-2 gene family whose activity is regulated by survival kinases such as AKT, in all three TNBC cell lines (<a href="#pone-0062170-g003">Figure 3A</a>). We next investigated the cell proliferation rates of TNBCs with miR-221 knockdown. Down-regulation of miR-221 in all three TNBC lines (MDA-MB-231, BT-20, MDA-MB-468) decreased cell proliferation rates (<a href="#pone-0062170-g003">Figure 3B</a>), likely due to the cell cycle block and increased apoptosis induced by miR-221 knockdown. Although we did not observe a significant increase of cleaved caspase 3 in MDA-MB-468 cells, miR-221 knockdown indeed was able to decrease pBAD (<a href="#pone-0062170-g003">Figure 3A</a>) and induced G1 arrests (<a href="#pone-0062170-g002">Figure 2E</a>) and subsequently resulted in cell proliferation inhibition probably through mitochondrial apoptosis regulated by BCL2 family <a href="#pone.0062170-Riedl1" class="ref-tip">[34]</a>, <a href="#pone.0062170-Tait1" class="ref-tip">[35]</a>.</p>
<a class="link-target" id="pone-0062170-g003" name="pone-0062170-g003"></a><div class="figure" data-doi="10.1371/journal.pone.0062170.g003"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=10.1371/journal.pone.0062170.g003" data-doi="10.1371/journal.pone.0062170" data-uri="10.1371/journal.pone.0062170.g003"><img src="article/figure/image?size=inline&amp;id=10.1371/journal.pone.0062170.g003" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pone.0062170.g003"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&amp;size=large&amp;id=10.1371/journal.pone.0062170.g003"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&amp;size=original&amp;id=10.1371/journal.pone.0062170.g003"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Figure 3. </span> miR-221 knockdown induces apoptosis, inhibits cell proliferation and supresses tumor growth in mice.</div><p class="caption_target"><a id="article1.body1.sec3.sec3.fig1.caption1.p1" name="article1.body1.sec3.sec3.fig1.caption1.p1" class="link-target"></a><p>MDA-MB-231, BT-20, and MDA-MB-468 cells stably expressing miR-221-ZIP or scramble-ZIP were used to perform apoptosis, cell proliferation, and <em>in-vivo</em> tumor growth assays. (A) Cleaved caspase 3 and phosphorylation of BAD were measured as apoptosis markers. All cell lines were seeded at similar density as the parental cell lines and cultured for 72 hours until the parental cell lines reached 80–95% confluencey, before cell lysates were prepared and subject to cleaved caspase 3 assays. (B) Cell proliferation measurements were normalized to the readings in parental cells at day 1. (C) Nude mice were implanted subcutaneously with MDA-MB-231 parental cells, and MDA-MB-231 cells stably expressing miR-221-ZIP or scramble-ZIP. Tumor measurements were recorded and tumor growth inhibition was calculated as described in <a href="#s2">Materials and Methods</a>. <em>T</em>-test was performed in (A) and (B) and one way ANOVA was performed in (C) to compare the differences between parental cells versus miR-221-ZIP cells. *denotes <em>p</em>-value ≤0.05. ***denotes <em>p</em>-value ≤0.005.</p>
</p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0062170.g003">
              https://doi.org/10.1371/journal.pone.0062170.g003</a></p></div><a id="article1.body1.sec3.sec3.p2" name="article1.body1.sec3.sec3.p2" class="link-target"></a><p>To expand on our <em>in vitro</em> results, we also investigated whether miR-221 is required for <em>in vivo</em> tumor growth. miR-221 stably knocked down MDA-MB-231 cells were implanted in nude mice and tumor growth was measured and plotted to compare with the tumor growth of MDA-MB-231 parental cell line and cells infected with the control ZIP vector alone as shown in <a href="#pone-0062170-g003">Figure 3C</a>. Our results indicated that miR-221 knockdown also inhibited <em>in vivo</em> tumor growth in TNBC cell line MDA-MB-231. Therefore, both the <em>in</em> <em>vitro</em> assays and <em>in vivo</em> studies confirm that miR-221 functions similar to an oncogene and is essential in mediating cell proliferation and tumor progression in TNBC.</p>
</div>

<div id="section4" class="section toc-section"><a id="s3d" name="s3d" class="link-target" title="miR-221 Modulates Cell Migration and Invasion by Regulating Epithelial-mesenchymal Transition"></a>
<h3>miR-221 Modulates Cell Migration and Invasion by Regulating Epithelial-mesenchymal Transition</h3>
<a id="article1.body1.sec3.sec4.p1" name="article1.body1.sec3.sec4.p1" class="link-target"></a><p>Relative to luminal subtypes, TNBCs, having undergone an epithelial to mesenchymal transition (EMT), express higher levels of vimentin and low levels of E-cadherin which allow for their characteristic high migration and invasion capabilities through the basement membrane to promote metastasis <a href="#pone.0062170-Thiery1" class="ref-tip">[36]</a>. Since miR-221 knockdown can inhibit cell proliferation and tumor growth in mice (<a href="#pone-0062170-g003">Figure 3</a>), we wanted to investigate the molecular mechanism for the miR-221 mediated cell transformation activity in TNBC human cell lines. Therefore, we next examined the levels of EMT markers and performed cell migration and invasion assays. The levels of E-cadherin and vimentin in a variety of breast cancer cells were quantified relative to the normal breast tissue as shown in <a href="#pone-0062170-g004">Figure 4A</a>. As expected, E-cadherin is highly expressed in luminal and HER2 positive cells but not in TNBC cell lines. Conversely, vimentin is expressed in higher levels in TNBC cell lines compared to non-TNBC cells. E-cadherin and vimentin levels were measured at both the transcript and protein levels in parental, vector control and miR-221 knocked down MDA-MB-231, BT-20, and MDA-MB-468 cells. Results indicate that knocking down miR-221 in these TNBCs significantly increased both the mRNA and protein levels of E-cadherin as shown in <a href="#pone-0062170-g004">Figure 4B</a>. Interestingly, vimentin levels were not altered by knocking down miR-221 in these cell lines. These data suggest that although suppression of E-cadherin is regulated by miR-221, the vimentin level in TNBCs is probably regulated by other mechanisms. Since E-cadherin lacks a miR221 binding site and is likely not a direct target, we next investigated if this regulation is mediated by any of the transcription factors that have previously been reported to directly regulate E-cadherin expression <a href="#pone.0062170-SanchezTillo1" class="ref-tip">[37]</a>. <a href="#pone-0062170-g004">Figure 4C</a> outlines the effects of miR-221 knockdown on some of the EMT transcription factors known to regulate E-cadherin levels. We observed a robust decrease in the expression levels of mesenchymal markers Snail and Slug by miR-221 knockdown in MDA-MB-231, BT20 and MDA-MB-468 (<a href="#pone-0062170-g004">Figure 4C</a>). As previously reported however, the expression level of Slug in MDA-MB-468 was much lower than the other two TNBC cell lines tested <a href="#pone.0062170-Hajra1" class="ref-tip">[38]</a>.</p>
<a class="link-target" id="pone-0062170-g004" name="pone-0062170-g004"></a><div class="figure" data-doi="10.1371/journal.pone.0062170.g004"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=10.1371/journal.pone.0062170.g004" data-doi="10.1371/journal.pone.0062170" data-uri="10.1371/journal.pone.0062170.g004"><img src="article/figure/image?size=inline&amp;id=10.1371/journal.pone.0062170.g004" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pone.0062170.g004"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&amp;size=large&amp;id=10.1371/journal.pone.0062170.g004"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&amp;size=original&amp;id=10.1371/journal.pone.0062170.g004"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Figure 4. </span> Down regulation of miR-221 increases E-cadherin levels and decreases the expression levels of Snail and Slug.</div><p class="caption_target"><a id="article1.body1.sec3.sec4.fig1.caption1.p1" name="article1.body1.sec3.sec4.fig1.caption1.p1" class="link-target"></a><p>(A) The RNA expression level of E-cadherin and vimentin was measured in a panel of breast cancer cell lines. Fold changes are recorded as normalized to normal breast tissue levels. (B) E-cadherin and vimentin expression levels were measured in MDA-MB-231, BT-20, MDA-MB-468 parental cells, as well cells harboring miR-221-ZIP, or scramble-ZIP. Data are normalized to the expression level in parental cells. Western blot analysis was also performed to examine the protein levels of E-cadherin and vimentin. (C) Snail and Slug expression levels were also examined in MDA-MB-231, BT-20, and MDA-MB-468 cells. Data were normalized to the expression level in parental cells and fold changes were plotted. ***denotes <em>p&lt;</em>0.005. **denotes <em>p&lt;</em>0.01.</p>
</p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0062170.g004">
              https://doi.org/10.1371/journal.pone.0062170.g004</a></p></div><a id="article1.body1.sec3.sec4.p2" name="article1.body1.sec3.sec4.p2" class="link-target"></a><p>We next investigated the effects of miR-221 knock down on cell migration and invasion of TNBC cell lines. As expected, MDA-MB-231, BT-20, and MDA-MB-468 showed high migratory and invasive properties in the migration and invasion assays performed upon stimulation with 10% FBS. Knocking down miR-221 decreased the FBS stimulated migration and invasion in all three cell lines as shown in <a href="#pone-0062170-g005">Figure 5A</a> and <a href="#pone-0062170-g005">Figure 5B</a>. Our data thus indicate that miR-221 alters the migration and invasion properties of TNBCs by suppressing E-cadherin expression. miR-221 knockdown in TNBCs restored E-cadherin expression and the increased E-cadherin in these TNBC cells was sufficient to block the activity of cell migration and invasion. Interestingly, although vimentin levels did not change with miR-221 knock down and high vimentin levels were maintained in these transduced TNBCs, it was not sufficient to maintain their migration and invasion capabilities. Therefore, these results suggest that the modulation of E-cadherin by miR-221 plays a critical role in maintaining the triple negative cell phenotype and knockdown of miR-221 can lead to increased E-cadherin and subsequently inhibit cell migration and invasion independent of vimentin levels.</p>
<a class="link-target" id="pone-0062170-g005" name="pone-0062170-g005"></a><div class="figure" data-doi="10.1371/journal.pone.0062170.g005"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=10.1371/journal.pone.0062170.g005" data-doi="10.1371/journal.pone.0062170" data-uri="10.1371/journal.pone.0062170.g005"><img src="article/figure/image?size=inline&amp;id=10.1371/journal.pone.0062170.g005" alt="thumbnail" class="thumbnail" loading="lazy"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><a href="article/figure/powerpoint?id=10.1371/journal.pone.0062170.g005"><div class="definition-label">PPT</div><div class="definition-description">PowerPoint slide</div></a></li><li><a href="article/figure/image?download&amp;size=large&amp;id=10.1371/journal.pone.0062170.g005"><div class="definition-label">PNG</div><div class="definition-description">larger image</div></a></li><li><a href="article/figure/image?download&amp;size=original&amp;id=10.1371/journal.pone.0062170.g005"><div class="definition-label">TIFF</div><div class="definition-description">original image</div></a></li></ul></div><div class="figcaption"><span>Figure 5. </span> Down regulation of miR-221 inhibits cell migration and invasion in TNBC lines.</div><p class="caption_target"><a id="article1.body1.sec3.sec4.fig2.caption1.p1" name="article1.body1.sec3.sec4.fig2.caption1.p1" class="link-target"></a><p>(A) Migration and (B) Invasion assays were performed in the absence or presence of 10% FBS after 72 hours in culture. Data are displayed as the percentage of cells migrated or invaded. <em>T</em>-test was performed to compare the differences between parental cells versus miR-221-ZIP cells, ***denotes <em>p&lt;</em>0.005.</p>
</p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0062170.g005">
              https://doi.org/10.1371/journal.pone.0062170.g005</a></p></div></div>
</div>

<div xmlns:plos="http://plos.org" id="section4" class="section toc-section"><a id="s4" name="s4" data-toc="s4" class="link-target" title="Discussion"></a><h2>Discussion</h2><a id="article1.body1.sec4.p1" name="article1.body1.sec4.p1" class="link-target"></a><p>miR-221 has been reported to be dysregulated in a variety of tumor types and has previously been shown to be involved in suppression of ERα expression in luminal breast cancer cells and EMT transition in basal-like breast cancers <a href="#pone.0062170-Zhao1" class="ref-tip">[23]</a>–<a href="#pone.0062170-Lu2" class="ref-tip">[26]</a>, <a href="#pone.0062170-Howe1" class="ref-tip">[29]</a>, <a href="#pone.0062170-Lambertini1" class="ref-tip">[30]</a>, <a href="#pone.0062170-Guttilla1" class="ref-tip">[39]</a>. Here we demonstrate that miR-221 is specifically over expressed in TNBCs and that miR-221 knockdown induces G1 arrest and apoptosis, inhibits cell proliferation and tumor growth (probably by altering expression levels of p27<sup>kip1</sup>), and suppresses the migratory phenotypes of TNBCs by restoring E-cadherin levels. These results suggest that miR-221 is essential in regulating the aggressive characteristics of triple negative or basal like of breast cancer cells, including cell proliferation, suppressed apoptosis, high migratory and invasive abilities, as well as accelerated <em>in-vivo</em> tumor growth. Therefore, our results provide direct evidence that overexpression of miR-221 leads to <em>in vitro</em> and <em>in vivo</em> tumorigenesis in TNBCs.</p>
<a id="article1.body1.sec4.p2" name="article1.body1.sec4.p2" class="link-target"></a><p>Therefore, miR-221 regulates two key mechanisms to promote the aggressive tumorogenic characteristics observed for TNBC: it promotes cell cycle progression by inhibiting p27<sup>kip1</sup> and it promotes EMT transition by inhibiting the expression of E-cadherin. Both of these mechanisms may account for the aggressive cellular proliferation, suppression of apoptosis, as well as higher cell migration and invasion characteristics associated with BLBCs and TNBCs <a href="#pone.0062170-Perou1" class="ref-tip">[9]</a>–<a href="#pone.0062170-Kang1" class="ref-tip">[11]</a>. Although, we could not rule out alternative targets of miR-221 that may explain the cellular phenotypes observed, knockdown of miR-221 alone is sufficient to induce <em>in vitro</em> and <em>in vivo</em> anti-tumor activities in the TNBC cell lines tested. Hence, the translational suppression of miR-221 targets is crucial in maintaining the aggressive tumor progression of TNBCs. Previously, miR-221 over expression has been shown to alter E-cadherin/vimentin levels in an EMT-induced MCF-7 cell line, which normally does not express endogenous miR-221 <a href="#pone.0062170-Guttilla1" class="ref-tip">[39]</a>. Additionally, EMT transcription factor Slug has previously been shown to decrease both miR-221 and E-cadherin/vimentin levels in MDA-MB-231 cells <a href="#pone.0062170-Lambertini1" class="ref-tip">[30]</a>. In this study, although we did observe changes in Slug and Snail, we did not detect changes in vimentin expression after stable miR-221 knockdown in MDA-MB-231, BT20, and MDA-MB-468 cell lines. Although vimentin levels were not altered, E-cadherin expression changed significantly with miR-221 knockdown. Our data suggest that increasing E-cadherin while maintaining vimentin levels in TNBCs seems to be sufficient for inhibiting cell migration and invasion. Therefore, E-cadherin seems to be critical in regulating cell motility, at least in the TNBC cell lines, MDA-MD-231, BT-20, and MDA-MB-468. Although miR-221 was able to regulate E-cadherin expression, we were unable to identify the complementary sequence in the 3′UTR of this protein. Therefore E-cadherin may not be a direct target of miR-221, and its expression is likely affected by alteration in EMT transcription factors Snail and Slug.</p>
<a id="article1.body1.sec4.p3" name="article1.body1.sec4.p3" class="link-target"></a><p>In conclusion, we have demonstrated that miR-221 is a potential oncomiR and functions as an oncogene to mediate tumor progression of TNBCs via targeting p27<sup>kip1</sup> and inhibiting E-cadherin levels to mediate EMT transition. These results may prove useful for therapeutic options for TNBCs when systemic delivery of anti-miR-221 becomes feasible.</p>
</div>





<div xmlns:plos="http://plos.org" class="section toc-section"><a id="ack" name="ack" data-toc="ack" title="Acknowledgments" class="link-target"></a><h2>Acknowledgments</h2>
<a id="article1.back1.ack1.p1" name="article1.back1.ack1.p1" class="link-target"></a><p>The authors would like to thank Tod Smeal, Timothy S Fisher, and Lars Engstrom for their help and support.</p>
</div><div xmlns:plos="http://plos.org" class="contributions toc-section"><a id="authcontrib" name="authcontrib" data-toc="authcontrib" title="Author Contributions"></a><h2>Author Contributions</h2><p>Conceived and designed the experiments: RN MJY. Performed the experiments: RN PPM SMB. Analyzed the data: RN MJY. Contributed reagents/materials/analysis tools: RN PPM SMB MJY. Wrote the paper: RN MJY.</p></div><div xmlns:plos="http://plos.org" class="toc-section"><a id="references" name="references" class="link-target" data-toc="references" title="References"></a><h2>References</h2><ol class="references"><li id="ref1"><span class="order">1.
            </span><a name="pone.0062170-Bartel1" id="pone.0062170-Bartel1" class="link-target"></a>Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297. <ul class="reflinks"><li><a href="#" data-author="Bartel" data-cit="BartelDP%20%282004%29%20MicroRNAs%3A%20genomics%2C%20biogenesis%2C%20mechanism%2C%20and%20function.%20Cell%20116%3A%20281%E2%80%93297." data-title="MicroRNAs%3A%20genomics%2C%20biogenesis%2C%20mechanism%2C%20and%20function" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=MicroRNAs%3A+genomics%2C+biogenesis%2C+mechanism%2C+and+function+Bartel+2004" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref2"><span class="order">2.
            </span><a name="pone.0062170-Lim1" id="pone.0062170-Lim1" class="link-target"></a>Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, et al. (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769–773. <ul class="reflinks"><li><a href="#" data-author="Lim" data-cit="LimLP%2C%20LauNC%2C%20Garrett-EngeleP%2C%20GrimsonA%2C%20SchelterJM%2C%20et%20al.%20%282005%29%20Microarray%20analysis%20shows%20that%20some%20microRNAs%20downregulate%20large%20numbers%20of%20target%20mRNAs.%20Nature%20433%3A%20769%E2%80%93773." data-title="Microarray%20analysis%20shows%20that%20some%20microRNAs%20downregulate%20large%20numbers%20of%20target%20mRNAs" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Microarray+analysis+shows+that+some+microRNAs+downregulate+large+numbers+of+target+mRNAs+Lim+2005" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref3"><span class="order">3.
            </span><a name="pone.0062170-Lewis1" id="pone.0062170-Lewis1" class="link-target"></a>Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. Cell 115: 787–798. <ul class="reflinks"><li><a href="#" data-author="Lewis" data-cit="LewisBP%2C%20ShihIH%2C%20Jones-RhoadesMW%2C%20BartelDP%2C%20BurgeCB%20%282003%29%20Prediction%20of%20mammalian%20microRNA%20targets.%20Cell%20115%3A%20787%E2%80%93798." data-title="Prediction%20of%20mammalian%20microRNA%20targets" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Prediction+of+mammalian+microRNA+targets+Lewis+2003" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref4"><span class="order">4.
            </span><a name="pone.0062170-EsquelaKerscher1" id="pone.0062170-EsquelaKerscher1" class="link-target"></a>Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259–269. <ul class="reflinks"><li><a href="#" data-author="Esquela-Kerscher" data-cit="Esquela-KerscherA%2C%20SlackFJ%20%282006%29%20Oncomirs%20-%20microRNAs%20with%20a%20role%20in%20cancer.%20Nat%20Rev%20Cancer%206%3A%20259%E2%80%93269." data-title="Oncomirs%20-%20microRNAs%20with%20a%20role%20in%20cancer" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Oncomirs+-+microRNAs+with+a+role+in+cancer+Esquela-Kerscher+2006" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref5"><span class="order">5.
            </span><a name="pone.0062170-Ambros1" id="pone.0062170-Ambros1" class="link-target"></a>Ambros V (2004) The functions of animal microRNAs. Nature 431: 350–355. <ul class="reflinks"><li><a href="#" data-author="Ambros" data-cit="AmbrosV%20%282004%29%20The%20functions%20of%20animal%20microRNAs.%20Nature%20431%3A%20350%E2%80%93355." data-title="The%20functions%20of%20animal%20microRNAs" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=The+functions+of+animal+microRNAs+Ambros+2004" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref6"><span class="order">6.
            </span><a name="pone.0062170-Calin1" id="pone.0062170-Calin1" class="link-target"></a>Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857–866. <ul class="reflinks"><li><a href="#" data-author="Calin" data-cit="CalinGA%2C%20CroceCM%20%282006%29%20MicroRNA%20signatures%20in%20human%20cancers.%20Nat%20Rev%20Cancer%206%3A%20857%E2%80%93866." data-title="MicroRNA%20signatures%20in%20human%20cancers" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=MicroRNA+signatures+in+human+cancers+Calin+2006" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref7"><span class="order">7.
            </span><a name="pone.0062170-Lu1" id="pone.0062170-Lu1" class="link-target"></a>Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834–838. <ul class="reflinks"><li><a href="#" data-author="Lu" data-cit="LuJ%2C%20GetzG%2C%20MiskaEA%2C%20Alvarez-SaavedraE%2C%20LambJ%2C%20et%20al.%20%282005%29%20MicroRNA%20expression%20profiles%20classify%20human%20cancers.%20Nature%20435%3A%20834%E2%80%93838." data-title="MicroRNA%20expression%20profiles%20classify%20human%20cancers" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=MicroRNA+expression+profiles+classify+human+cancers+Lu+2005" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref8"><span class="order">8.
            </span><a name="pone.0062170-Calin2" id="pone.0062170-Calin2" class="link-target"></a>Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101: 2999–3004. <ul class="reflinks"><li><a href="#" data-author="Calin" data-cit="CalinGA%2C%20SevignaniC%2C%20DumitruCD%2C%20HyslopT%2C%20NochE%2C%20et%20al.%20%282004%29%20Human%20microRNA%20genes%20are%20frequently%20located%20at%20fragile%20sites%20and%20genomic%20regions%20involved%20in%20cancers.%20Proc%20Natl%20Acad%20Sci%20U%20S%20A%20101%3A%202999%E2%80%933004." data-title="Human%20microRNA%20genes%20are%20frequently%20located%20at%20fragile%20sites%20and%20genomic%20regions%20involved%20in%20cancers" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Human+microRNA+genes+are+frequently+located+at+fragile+sites+and+genomic+regions+involved+in+cancers+Calin+2004" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref9"><span class="order">9.
            </span><a name="pone.0062170-Perou1" id="pone.0062170-Perou1" class="link-target"></a>Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752. <ul class="reflinks"><li><a href="#" data-author="Perou" data-cit="PerouCM%2C%20SorlieT%2C%20EisenMB%2C%20van%20de%20RijnM%2C%20JeffreySS%2C%20et%20al.%20%282000%29%20Molecular%20portraits%20of%20human%20breast%20tumours.%20Nature%20406%3A%20747%E2%80%93752." data-title="Molecular%20portraits%20of%20human%20breast%20tumours" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Molecular+portraits+of+human+breast+tumours+Perou+2000" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref10"><span class="order">10.
            </span><a name="pone.0062170-Sorlie1" id="pone.0062170-Sorlie1" class="link-target"></a>Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869–10874. <ul class="reflinks"><li><a href="#" data-author="Sorlie" data-cit="SorlieT%2C%20PerouCM%2C%20TibshiraniR%2C%20AasT%2C%20GeislerS%2C%20et%20al.%20%282001%29%20Gene%20expression%20patterns%20of%20breast%20carcinomas%20distinguish%20tumor%20subclasses%20with%20clinical%20implications.%20Proc%20Natl%20Acad%20Sci%20U%20S%20A%2098%3A%2010869%E2%80%9310874." data-title="Gene%20expression%20patterns%20of%20breast%20carcinomas%20distinguish%20tumor%20subclasses%20with%20clinical%20implications" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Gene+expression+patterns+of+breast+carcinomas+distinguish+tumor+subclasses+with+clinical+implications+Sorlie+2001" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref11"><span class="order">11.
            </span><a name="pone.0062170-Kang1" id="pone.0062170-Kang1" class="link-target"></a>Kang SP, Martel M, Harris LN (2008) Triple negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol 20: 40–46. <ul class="reflinks"><li><a href="#" data-author="Kang" data-cit="KangSP%2C%20MartelM%2C%20HarrisLN%20%282008%29%20Triple%20negative%20breast%20cancer%3A%20current%20understanding%20of%20biology%20and%20treatment%20options.%20Curr%20Opin%20Obstet%20Gynecol%2020%3A%2040%E2%80%9346." data-title="Triple%20negative%20breast%20cancer%3A%20current%20understanding%20of%20biology%20and%20treatment%20options" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Triple+negative+breast+cancer%3A+current+understanding+of+biology+and+treatment+options+Kang+2008" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref12"><span class="order">12.
            </span><a name="pone.0062170-Bidard1" id="pone.0062170-Bidard1" class="link-target"></a>Bidard FC, Conforti R, Boulet T, Michiels S, Delaloge S, et al. (2007) Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. Ann Oncol 18: 1285–1286. <ul class="reflinks"><li><a href="#" data-author="Bidard" data-cit="BidardFC%2C%20ConfortiR%2C%20BouletT%2C%20MichielsS%2C%20DelalogeS%2C%20et%20al.%20%282007%29%20Does%20triple-negative%20phenotype%20accurately%20identify%20basal-like%20tumour%3F%20An%20immunohistochemical%20analysis%20based%20on%20143%20%27triple-negative%27%20breast%20cancers.%20Ann%20Oncol%2018%3A%201285%E2%80%931286." data-title="Does%20triple-negative%20phenotype%20accurately%20identify%20basal-like%20tumour%3F%20An%20immunohistochemical%20analysis%20based%20on%20143%20%26apos%3Btriple-negative%26apos%3B%20breast%20cancers" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Does+triple-negative+phenotype+accurately+identify+basal-like+tumour%3F+An+immunohistochemical+analysis+based+on+143+%26apos%3Btriple-negative%26apos%3B+breast+cancers+Bidard+2007" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref13"><span class="order">13.
            </span><a name="pone.0062170-Rakha1" id="pone.0062170-Rakha1" class="link-target"></a>Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Pathology 41: 40–47. <ul class="reflinks"><li><a href="#" data-author="Rakha" data-cit="RakhaEA%2C%20EllisIO%20%282009%29%20Triple-negative%2Fbasal-like%20breast%20cancer%3A%20review.%20Pathology%2041%3A%2040%E2%80%9347." data-title="Triple-negative%2Fbasal-like%20breast%20cancer%3A%20review" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Triple-negative%2Fbasal-like+breast+cancer%3A+review+Rakha+2009" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref14"><span class="order">14.
            </span><a name="pone.0062170-Carey1" id="pone.0062170-Carey1" class="link-target"></a>Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492–2502. <ul class="reflinks"><li><a href="#" data-author="Carey" data-cit="CareyLA%2C%20PerouCM%2C%20LivasyCA%2C%20DresslerLG%2C%20CowanD%2C%20et%20al.%20%282006%29%20Race%2C%20breast%20cancer%20subtypes%2C%20and%20survival%20in%20the%20Carolina%20Breast%20Cancer%20Study.%20JAMA%20295%3A%202492%E2%80%932502." data-title="Race%2C%20breast%20cancer%20subtypes%2C%20and%20survival%20in%20the%20Carolina%20Breast%20Cancer%20Study" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Race%2C+breast+cancer+subtypes%2C+and+survival+in+the+Carolina+Breast+Cancer+Study+Carey+2006" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref15"><span class="order">15.
            </span><a name="pone.0062170-Dent1" id="pone.0062170-Dent1" class="link-target"></a>Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429–4434. <ul class="reflinks"><li><a href="#" data-author="Dent" data-cit="DentR%2C%20TrudeauM%2C%20PritchardKI%2C%20HannaWM%2C%20KahnHK%2C%20et%20al.%20%282007%29%20Triple-negative%20breast%20cancer%3A%20clinical%20features%20and%20patterns%20of%20recurrence.%20Clin%20Cancer%20Res%2013%3A%204429%E2%80%934434." data-title="Triple-negative%20breast%20cancer%3A%20clinical%20features%20and%20patterns%20of%20recurrence" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Triple-negative+breast+cancer%3A+clinical+features+and+patterns+of+recurrence+Dent+2007" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref16"><span class="order">16.
            </span><a name="pone.0062170-Gramantieri1" id="pone.0062170-Gramantieri1" class="link-target"></a>Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, et al. (2009) MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res 15: 5073–5081. <ul class="reflinks"><li><a href="#" data-author="Gramantieri" data-cit="GramantieriL%2C%20FornariF%2C%20FerracinM%2C%20VeroneseA%2C%20SabbioniS%2C%20et%20al.%20%282009%29%20MicroRNA-221%20targets%20Bmf%20in%20hepatocellular%20carcinoma%20and%20correlates%20with%20tumor%20multifocality.%20Clin%20Cancer%20Res%2015%3A%205073%E2%80%935081." data-title="MicroRNA-221%20targets%20Bmf%20in%20hepatocellular%20carcinoma%20and%20correlates%20with%20tumor%20multifocality" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=MicroRNA-221+targets+Bmf+in+hepatocellular+carcinoma+and+correlates+with+tumor+multifocality+Gramantieri+2009" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref17"><span class="order">17.
            </span><a name="pone.0062170-Galardi1" id="pone.0062170-Galardi1" class="link-target"></a>Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, et al. (2007) miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 282: 23716–23724. <ul class="reflinks"><li><a href="#" data-author="Galardi" data-cit="GalardiS%2C%20MercatelliN%2C%20GiordaE%2C%20MassaliniS%2C%20FrajeseGV%2C%20et%20al.%20%282007%29%20miR-221%20and%20miR-222%20expression%20affects%20the%20proliferation%20potential%20of%20human%20prostate%20carcinoma%20cell%20lines%20by%20targeting%20p27Kip1.%20J%20Biol%20Chem%20282%3A%2023716%E2%80%9323724." data-title="miR-221%20and%20miR-222%20expression%20affects%20the%20proliferation%20potential%20of%20human%20prostate%20carcinoma%20cell%20lines%20by%20targeting%20p27Kip1" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=miR-221+and+miR-222+expression+affects+the+proliferation+potential+of+human+prostate+carcinoma+cell+lines+by+targeting+p27Kip1+Galardi+2007" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref18"><span class="order">18.
            </span><a name="pone.0062170-Garofalo1" id="pone.0062170-Garofalo1" class="link-target"></a>Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, et al. (2009) miR-221&amp;222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16: 498–509. <ul class="reflinks"><li><a href="#" data-author="Garofalo" data-cit="GarofaloM%2C%20Di%20LevaG%2C%20RomanoG%2C%20NuovoG%2C%20SuhSS%2C%20et%20al.%20%282009%29%20miR-221%26222%20regulate%20TRAIL%20resistance%20and%20enhance%20tumorigenicity%20through%20PTEN%20and%20TIMP3%20downregulation.%20Cancer%20Cell%2016%3A%20498%E2%80%93509." data-title="miR-221%26amp%3B222%20regulate%20TRAIL%20resistance%20and%20enhance%20tumorigenicity%20through%20PTEN%20and%20TIMP3%20downregulation" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=miR-221%26amp%3B222+regulate+TRAIL+resistance+and+enhance+tumorigenicity+through+PTEN+and+TIMP3+downregulation+Garofalo+2009" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref19"><span class="order">19.
            </span><a name="pone.0062170-Kim1" id="pone.0062170-Kim1" class="link-target"></a>Kim D, Song J, Jin EJ (2010) MicroRNA-221 regulates chondrogenic differentiation through promoting proteosomal degradation of slug by targeting Mdm2. J Biol Chem 285: 26900–26907. <ul class="reflinks"><li><a href="#" data-author="Kim" data-cit="KimD%2C%20SongJ%2C%20JinEJ%20%282010%29%20MicroRNA-221%20regulates%20chondrogenic%20differentiation%20through%20promoting%20proteosomal%20degradation%20of%20slug%20by%20targeting%20Mdm2.%20J%20Biol%20Chem%20285%3A%2026900%E2%80%9326907." data-title="MicroRNA-221%20regulates%20chondrogenic%20differentiation%20through%20promoting%20proteosomal%20degradation%20of%20slug%20by%20targeting%20Mdm2" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=MicroRNA-221+regulates+chondrogenic+differentiation+through+promoting+proteosomal+degradation+of+slug+by+targeting+Mdm2+Kim+2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref20"><span class="order">20.
            </span><a name="pone.0062170-Sun1" id="pone.0062170-Sun1" class="link-target"></a>Sun T, Wang Q, Balk S, Brown M, Lee GS, et al. (2009) The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 69: 3356–3363. <ul class="reflinks"><li><a href="#" data-author="Sun" data-cit="SunT%2C%20WangQ%2C%20BalkS%2C%20BrownM%2C%20LeeGS%2C%20et%20al.%20%282009%29%20The%20role%20of%20microRNA-221%20and%20microRNA-222%20in%20androgen-independent%20prostate%20cancer%20cell%20lines.%20Cancer%20Res%2069%3A%203356%E2%80%933363." data-title="The%20role%20of%20microRNA-221%20and%20microRNA-222%20in%20androgen-independent%20prostate%20cancer%20cell%20lines" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=The+role+of+microRNA-221+and+microRNA-222+in+androgen-independent+prostate+cancer+cell+lines+Sun+2009" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref21"><span class="order">21.
            </span><a name="pone.0062170-Zhang1" id="pone.0062170-Zhang1" class="link-target"></a>Zhang C, Zhang J, Zhang A, Wang Y, Han L, et al. (2010) PUMA is a novel target of miR-221/222 in human epithelial cancers. Int J Oncol 37: 1621–1626. <ul class="reflinks"><li><a href="#" data-author="Zhang" data-cit="ZhangC%2C%20ZhangJ%2C%20ZhangA%2C%20WangY%2C%20HanL%2C%20et%20al.%20%282010%29%20PUMA%20is%20a%20novel%20target%20of%20miR-221%2F222%20in%20human%20epithelial%20cancers.%20Int%20J%20Oncol%2037%3A%201621%E2%80%931626." data-title="PUMA%20is%20a%20novel%20target%20of%20miR-221%2F222%20in%20human%20epithelial%20cancers" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=PUMA+is+a+novel+target+of+miR-221%2F222+in+human+epithelial+cancers+Zhang+2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref22"><span class="order">22.
            </span><a name="pone.0062170-Stinson1" id="pone.0062170-Stinson1" class="link-target"></a>Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, et al. (2011) TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal 4: ra41. <ul class="reflinks"><li><a href="#" data-author="Stinson" data-cit="StinsonS%2C%20LacknerMR%2C%20AdaiAT%2C%20YuN%2C%20KimHJ%2C%20et%20al.%20%282011%29%20TRPS1%20targeting%20by%20miR-221%2F222%20promotes%20the%20epithelial-to-mesenchymal%20transition%20in%20breast%20cancer.%20Sci%20Signal%204%3A%20ra41." data-title="TRPS1%20targeting%20by%20miR-221%2F222%20promotes%20the%20epithelial-to-mesenchymal%20transition%20in%20breast%20cancer" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=TRPS1+targeting+by+miR-221%2F222+promotes+the+epithelial-to-mesenchymal+transition+in+breast+cancer+Stinson+2011" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref23"><span class="order">23.
            </span><a name="pone.0062170-Zhao1" id="pone.0062170-Zhao1" class="link-target"></a>Zhao JJ, Lin J, Yang H, Kong W, He L, et al. (2008) MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283: 31079–31086. <ul class="reflinks"><li><a href="#" data-author="Zhao" data-cit="ZhaoJJ%2C%20LinJ%2C%20YangH%2C%20KongW%2C%20HeL%2C%20et%20al.%20%282008%29%20MicroRNA-221%2F222%20negatively%20regulates%20estrogen%20receptor%20alpha%20and%20is%20associated%20with%20tamoxifen%20resistance%20in%20breast%20cancer.%20J%20Biol%20Chem%20283%3A%2031079%E2%80%9331086." data-title="MicroRNA-221%2F222%20negatively%20regulates%20estrogen%20receptor%20alpha%20and%20is%20associated%20with%20tamoxifen%20resistance%20in%20breast%20cancer" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=MicroRNA-221%2F222+negatively+regulates+estrogen+receptor+alpha+and+is+associated+with+tamoxifen+resistance+in+breast+cancer+Zhao+2008" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref24"><span class="order">24.
            </span><a name="pone.0062170-Miller1" id="pone.0062170-Miller1" class="link-target"></a>Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, et al. (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283: 29897–29903. <ul class="reflinks"><li><a href="#" data-author="Miller" data-cit="MillerTE%2C%20GhoshalK%2C%20RamaswamyB%2C%20RoyS%2C%20DattaJ%2C%20et%20al.%20%282008%29%20MicroRNA-221%2F222%20confers%20tamoxifen%20resistance%20in%20breast%20cancer%20by%20targeting%20p27Kip1.%20J%20Biol%20Chem%20283%3A%2029897%E2%80%9329903." data-title="MicroRNA-221%2F222%20confers%20tamoxifen%20resistance%20in%20breast%20cancer%20by%20targeting%20p27Kip1" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=MicroRNA-221%2F222+confers+tamoxifen+resistance+in+breast+cancer+by+targeting+p27Kip1+Miller+2008" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref25"><span class="order">25.
            </span><a name="pone.0062170-Rao1" id="pone.0062170-Rao1" class="link-target"></a>Rao X, Di Leva G, Li M, Fang F, Devlin C, et al. (2011) MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 30: 1082–1097. <ul class="reflinks"><li><a href="#" data-author="Rao" data-cit="RaoX%2C%20Di%20LevaG%2C%20LiM%2C%20FangF%2C%20DevlinC%2C%20et%20al.%20%282011%29%20MicroRNA-221%2F222%20confers%20breast%20cancer%20fulvestrant%20resistance%20by%20regulating%20multiple%20signaling%20pathways.%20Oncogene%2030%3A%201082%E2%80%931097." data-title="MicroRNA-221%2F222%20confers%20breast%20cancer%20fulvestrant%20resistance%20by%20regulating%20multiple%20signaling%20pathways" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=MicroRNA-221%2F222+confers+breast+cancer+fulvestrant+resistance+by+regulating+multiple+signaling+pathways+Rao+2011" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref26"><span class="order">26.
            </span><a name="pone.0062170-Lu2" id="pone.0062170-Lu2" class="link-target"></a>Lu Y, Roy S, Nuovo G, Ramaswamy B, Miller T, et al. (2011) Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem 286: 42292–42302. <ul class="reflinks"><li><a href="#" data-author="Lu" data-cit="LuY%2C%20RoyS%2C%20NuovoG%2C%20RamaswamyB%2C%20MillerT%2C%20et%20al.%20%282011%29%20Anti-microRNA-222%20%28anti-miR-222%29%20and%20-181B%20suppress%20growth%20of%20tamoxifen-resistant%20xenografts%20in%20mouse%20by%20targeting%20TIMP3%20protein%20and%20modulating%20mitogenic%20signal.%20J%20Biol%20Chem%20286%3A%2042292%E2%80%9342302." data-title="Anti-microRNA-222%20%28anti-miR-222%29%20and%20-181B%20suppress%20growth%20of%20tamoxifen-resistant%20xenografts%20in%20mouse%20by%20targeting%20TIMP3%20protein%20and%20modulating%20mitogenic%20signal" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Anti-microRNA-222+%28anti-miR-222%29+and+-181B+suppress+growth+of+tamoxifen-resistant+xenografts+in+mouse+by+targeting+TIMP3+protein+and+modulating+mitogenic+signal+Lu+2011" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref27"><span class="order">27.
            </span><a name="pone.0062170-Cochrane1" id="pone.0062170-Cochrane1" class="link-target"></a>Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, et al. (2010) MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer 1: 306–319. <ul class="reflinks"><li><a href="#" data-author="Cochrane" data-cit="CochraneDR%2C%20CittellyDM%2C%20HoweEN%2C%20SpoelstraNS%2C%20McKinseyEL%2C%20et%20al.%20%282010%29%20MicroRNAs%20link%20estrogen%20receptor%20alpha%20status%20and%20Dicer%20levels%20in%20breast%20cancer.%20Horm%20Cancer%201%3A%20306%E2%80%93319." data-title="MicroRNAs%20link%20estrogen%20receptor%20alpha%20status%20and%20Dicer%20levels%20in%20breast%20cancer" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=MicroRNAs+link+estrogen+receptor+alpha+status+and+Dicer+levels+in+breast+cancer+Cochrane+2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref28"><span class="order">28.
            </span><a name="pone.0062170-Radojicic1" id="pone.0062170-Radojicic1" class="link-target"></a>Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, et al. (2011) MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 10: 507–517. <ul class="reflinks"><li><a href="#" data-author="Radojicic" data-cit="RadojicicJ%2C%20ZaravinosA%2C%20VrekoussisT%2C%20KafousiM%2C%20SpandidosDA%2C%20et%20al.%20%282011%29%20MicroRNA%20expression%20analysis%20in%20triple-negative%20%28ER%2C%20PR%20and%20Her2%2Fneu%29%20breast%20cancer.%20Cell%20Cycle%2010%3A%20507%E2%80%93517." data-title="MicroRNA%20expression%20analysis%20in%20triple-negative%20%28ER%2C%20PR%20and%20Her2%2Fneu%29%20breast%20cancer" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=MicroRNA+expression+analysis+in+triple-negative+%28ER%2C+PR+and+Her2%2Fneu%29+breast+cancer+Radojicic+2011" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref29"><span class="order">29.
            </span><a name="pone.0062170-Howe1" id="pone.0062170-Howe1" class="link-target"></a>Howe EN, Cochrane DR, Richer JK (2012) The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia 17: 65–77. <ul class="reflinks"><li><a href="#" data-author="Howe" data-cit="HoweEN%2C%20CochraneDR%2C%20RicherJK%20%282012%29%20The%20miR-200%20and%20miR-221%2F222%20microRNA%20families%3A%20opposing%20effects%20on%20epithelial%20identity.%20J%20Mammary%20Gland%20Biol%20Neoplasia%2017%3A%2065%E2%80%9377." data-title="The%20miR-200%20and%20miR-221%2F222%20microRNA%20families%3A%20opposing%20effects%20on%20epithelial%20identity" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=The+miR-200+and+miR-221%2F222+microRNA+families%3A+opposing+effects+on+epithelial+identity+Howe+2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref30"><span class="order">30.
            </span><a name="pone.0062170-Lambertini1" id="pone.0062170-Lambertini1" class="link-target"></a>Lambertini E, Lolli A, Vezzali F, Penolazzi L, Gambari R, et al. (2012) Correlation between Slug transcription factor and miR-221 in MDA-MB-231 breast cancer cells. BMC Cancer 12: 445. <ul class="reflinks"><li><a href="#" data-author="Lambertini" data-cit="LambertiniE%2C%20LolliA%2C%20VezzaliF%2C%20PenolazziL%2C%20GambariR%2C%20et%20al.%20%282012%29%20Correlation%20between%20Slug%20transcription%20factor%20and%20miR-221%20in%20MDA-MB-231%20breast%20cancer%20cells.%20BMC%20Cancer%2012%3A%20445." data-title="Correlation%20between%20Slug%20transcription%20factor%20and%20miR-221%20in%20MDA-MB-231%20breast%20cancer%20cells" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Correlation+between+Slug+transcription+factor+and+miR-221+in+MDA-MB-231+breast+cancer+cells+Lambertini+2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref31"><span class="order">31.
            </span><a name="pone.0062170-leSage1" id="pone.0062170-leSage1" class="link-target"></a>le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, et al. (2007) Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 26: 3699–3708. <ul class="reflinks"><li><a href="#" data-author="le%20Sage" data-cit="le%20SageC%2C%20NagelR%2C%20EganDA%2C%20SchrierM%2C%20MesmanE%2C%20et%20al.%20%282007%29%20Regulation%20of%20the%20p27%28Kip1%29%20tumor%20suppressor%20by%20miR-221%20and%20miR-222%20promotes%20cancer%20cell%20proliferation.%20EMBO%20J%2026%3A%203699%E2%80%933708." data-title="Regulation%20of%20the%20p27%28Kip1%29%20tumor%20suppressor%20by%20miR-221%20and%20miR-222%20promotes%20cancer%20cell%20proliferation" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Regulation+of+the+p27%28Kip1%29+tumor+suppressor+by+miR-221+and+miR-222+promotes+cancer+cell+proliferation+le+Sage+2007" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref32"><span class="order">32.
            </span><a name="pone.0062170-Fornari1" id="pone.0062170-Fornari1" class="link-target"></a>Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, et al. (2008) MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 27: 5651–5661. <ul class="reflinks"><li><a href="#" data-author="Fornari" data-cit="FornariF%2C%20GramantieriL%2C%20FerracinM%2C%20VeroneseA%2C%20SabbioniS%2C%20et%20al.%20%282008%29%20MiR-221%20controls%20CDKN1C%2Fp57%20and%20CDKN1B%2Fp27%20expression%20in%20human%20hepatocellular%20carcinoma.%20Oncogene%2027%3A%205651%E2%80%935661." data-title="MiR-221%20controls%20CDKN1C%2Fp57%20and%20CDKN1B%2Fp27%20expression%20in%20human%20hepatocellular%20carcinoma" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=MiR-221+controls+CDKN1C%2Fp57+and+CDKN1B%2Fp27+expression+in+human+hepatocellular+carcinoma+Fornari+2008" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref33"><span class="order">33.
            </span><a name="pone.0062170-Lu3" id="pone.0062170-Lu3" class="link-target"></a>Lu Z, Hunter T (2010) Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. Cell Cycle 9: 2342–2352. <ul class="reflinks"><li><a href="#" data-author="Lu" data-cit="LuZ%2C%20HunterT%20%282010%29%20Ubiquitylation%20and%20proteasomal%20degradation%20of%20the%20p21%28Cip1%29%2C%20p27%28Kip1%29%20and%20p57%28Kip2%29%20CDK%20inhibitors.%20Cell%20Cycle%209%3A%202342%E2%80%932352." data-title="Ubiquitylation%20and%20proteasomal%20degradation%20of%20the%20p21%28Cip1%29%2C%20p27%28Kip1%29%20and%20p57%28Kip2%29%20CDK%20inhibitors" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Ubiquitylation+and+proteasomal+degradation+of+the+p21%28Cip1%29%2C+p27%28Kip1%29+and+p57%28Kip2%29+CDK+inhibitors+Lu+2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref34"><span class="order">34.
            </span><a name="pone.0062170-Riedl1" id="pone.0062170-Riedl1" class="link-target"></a>Riedl SJ, Shi Y (2004) Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5: 897–907. <ul class="reflinks"><li><a href="#" data-author="Riedl" data-cit="RiedlSJ%2C%20ShiY%20%282004%29%20Molecular%20mechanisms%20of%20caspase%20regulation%20during%20apoptosis.%20Nat%20Rev%20Mol%20Cell%20Biol%205%3A%20897%E2%80%93907." data-title="Molecular%20mechanisms%20of%20caspase%20regulation%20during%20apoptosis" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Molecular+mechanisms+of+caspase+regulation+during+apoptosis+Riedl+2004" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref35"><span class="order">35.
            </span><a name="pone.0062170-Tait1" id="pone.0062170-Tait1" class="link-target"></a>Tait SW, Green DR (2010) Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11: 621–632. <ul class="reflinks"><li><a href="#" data-author="Tait" data-cit="TaitSW%2C%20GreenDR%20%282010%29%20Mitochondria%20and%20cell%20death%3A%20outer%20membrane%20permeabilization%20and%20beyond.%20Nat%20Rev%20Mol%20Cell%20Biol%2011%3A%20621%E2%80%93632." data-title="Mitochondria%20and%20cell%20death%3A%20outer%20membrane%20permeabilization%20and%20beyond" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Mitochondria+and+cell+death%3A+outer+membrane+permeabilization+and+beyond+Tait+2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref36"><span class="order">36.
            </span><a name="pone.0062170-Thiery1" id="pone.0062170-Thiery1" class="link-target"></a>Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871–890. <ul class="reflinks"><li><a href="#" data-author="Thiery" data-cit="ThieryJP%2C%20AcloqueH%2C%20HuangRY%2C%20NietoMA%20%282009%29%20Epithelial-mesenchymal%20transitions%20in%20development%20and%20disease.%20Cell%20139%3A%20871%E2%80%93890." data-title="Epithelial-mesenchymal%20transitions%20in%20development%20and%20disease" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Epithelial-mesenchymal+transitions+in+development+and+disease+Thiery+2009" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref37"><span class="order">37.
            </span><a name="pone.0062170-SanchezTillo1" id="pone.0062170-SanchezTillo1" class="link-target"></a>Sanchez-Tillo E, Liu Y, de Barrios O, Siles L, Fanlo L, et al. (2012) EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci 69: 3429–3456. <ul class="reflinks"><li><a href="#" data-author="Sanchez-Tillo" data-cit="Sanchez-TilloE%2C%20LiuY%2C%20de%20BarriosO%2C%20SilesL%2C%20FanloL%2C%20et%20al.%20%282012%29%20EMT-activating%20transcription%20factors%20in%20cancer%3A%20beyond%20EMT%20and%20tumor%20invasiveness.%20Cell%20Mol%20Life%20Sci%2069%3A%203429%E2%80%933456." data-title="EMT-activating%20transcription%20factors%20in%20cancer%3A%20beyond%20EMT%20and%20tumor%20invasiveness" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=EMT-activating+transcription+factors+in+cancer%3A+beyond+EMT+and+tumor+invasiveness+Sanchez-Tillo+2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref38"><span class="order">38.
            </span><a name="pone.0062170-Hajra1" id="pone.0062170-Hajra1" class="link-target"></a>Hajra KM, Chen DY, Fearon ER (2002) The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 62: 1613–1618. <ul class="reflinks"><li><a href="#" data-author="Hajra" data-cit="HajraKM%2C%20ChenDY%2C%20FearonER%20%282002%29%20The%20SLUG%20zinc-finger%20protein%20represses%20E-cadherin%20in%20breast%20cancer.%20Cancer%20Res%2062%3A%201613%E2%80%931618." data-title="The%20SLUG%20zinc-finger%20protein%20represses%20E-cadherin%20in%20breast%20cancer" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=The+SLUG+zinc-finger+protein+represses+E-cadherin+in+breast+cancer+Hajra+2002" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref39"><span class="order">39.
            </span><a name="pone.0062170-Guttilla1" id="pone.0062170-Guttilla1" class="link-target"></a>Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP, et al. (2012) Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat 132: 75–85. <ul class="reflinks"><li><a href="#" data-author="Guttilla" data-cit="GuttillaIK%2C%20PhoenixKN%2C%20HongX%2C%20TirnauerJS%2C%20ClaffeyKP%2C%20et%20al.%20%282012%29%20Prolonged%20mammosphere%20culture%20of%20MCF-7%20cells%20induces%20an%20EMT%20and%20repression%20of%20the%20estrogen%20receptor%20by%20microRNAs.%20Breast%20Cancer%20Res%20Treat%20132%3A%2075%E2%80%9385." data-title="Prolonged%20mammosphere%20culture%20of%20MCF-7%20cells%20induces%20an%20EMT%20and%20repression%20of%20the%20estrogen%20receptor%20by%20microRNAs" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://scholar.google.com/scholar?q=Prolonged+mammosphere+culture+of+MCF-7+cells+induces+an+EMT+and+repression+of+the+estrogen+receptor+by+microRNAs+Guttilla+2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li></ol></div>



          <div class="ref-tooltip">
            <div class="ref_tooltip-content">

            </div>
          </div>

        </div>
      </div>
    </div>

  </section>
  <aside class="article-aside">


<!--[if IE 9]>
<style>
.dload-xml {margin-top: 38px}
</style>
<![endif]-->
<div class="dload-menu">
  <div class="dload-pdf">
    <a href="/plosone/article/file?id=10.1371/journal.pone.0062170&type=printable"
       id="downloadPdf" target="_blank">Download PDF</a>
  </div>
  <div data-js-tooltip-hover="trigger" class="dload-hover">&nbsp;
    <ul class="dload-xml" data-js-tooltip-hover="target">
      <li><a href="/plosone/article/citation?id=10.1371/journal.pone.0062170"
             id="downloadCitation">Citation</a></li>
      <li><a href="/plosone/article/file?id=10.1371/journal.pone.0062170&type=manuscript"
             id="downloadXml">XML</a>
      </li>
    </ul>

  </div>
</div>

<div class="aside-container">

<div class="print-article" id="printArticle" data-js-tooltip-hover="trigger">

  Print
  <ul class="print-options" data-js-tooltip-hover="target">
    <li><a href="#" onclick="window.print(); return false;" class="preventDefault" id="printBrowser">Print article</a></li>

<li><a href="http://surveys.plos.org/s3/reprints">Reprints</a></li>

  </ul>
</div>

<div class="share-article" id="shareArticle" data-js-tooltip-hover="trigger">
  Share
  <ul data-js-tooltip-hover="target" class="share-options" id="share-options">

<li><a href="https://www.reddit.com/submit?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0062170" id="shareReddit" target="_blank" title="Submit to Reddit"><img src="/resource/img/icon.reddit.16.png" width="16" height="16" alt="Reddit">Reddit</a></li>

<li><a href="https://www.facebook.com/share.php?u=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0062170&t=miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells" id="shareFacebook" target="_blank" title="Share on Facebook"><img src="/resource/img/icon.fb.16.png" width="16" height="16" alt="Facebook">Facebook</a></li>


<li><a href="https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0062170&title=miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells&summary=Checkout this article I found at PLOS"  id="shareLinkedIn" target="_blank" title="Add to LinkedIn"><img src="/resource/img/icon.linkedin.16.png" width="16" height="16" alt="LinkedIn">LinkedIn</a></li>

<li><a href="https://www.mendeley.com/import/?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0062170"  id="shareMendeley" target="_blank" title="Add to Mendeley"><img src="/resource/img/icon.mendeley.16.png" width="16" height="16" alt="Mendeley">Mendeley</a></li>

  <li><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0062170&text=%23PLOSONE%3A%20miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells" target="_blank" title="share on Twitter" id="twitter-share-link"><img src="/resource/img/icon.twtr.16.png" width="16" height="16" alt="Twitter">Twitter</a></li>

<li><a href="mailto:?subject=miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells&body=I%20thought%20you%20would%20find%20this%20article%20interesting.%20From%20PLOS ONE:%20https%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0062170"  id="shareEmail" rel="noreferrer" aria-label="Email"><img src="/resource/img/icon.email.16.png" width="16" height="16" alt="Email">Email</a></li>
<script src="/resource/js/components/tweet140.js" type="text/javascript"></script>
  </ul>
</div></div>


     <!-- Crossmark 2.0 widget -->
    <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script>
    <a aria-label="Check for updates via CrossMark" data-target="crossmark">
      <img alt="Check for updates via CrossMark" width="150" src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_BW_horizontal.svg">
    </a>
    <!-- End Crossmark 2.0 widget -->


  <div class="related-articles-container">
    <h3>
Related PLOS Articles
</h3>
    <ul class="related-articles">
        <li>
          <b>
            has RETRACTION
            
          </b>
        </li>
            <li>
<?xml version="1.0" encoding="UTF-8"?>Retraction: miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells              <ul class="related-article-links">
                <li class="related-article-link-page">
                  <a href="/plosone/article?id=10.1371/journal.pone.0175869">View Page</a>
                </li>
                <!--  Annotations and issue images do not have printables. They can be filtered by doi. -->
                  <li class="related-article-link-download">
                    <a href="/plosone/article/file?type=printable&id=10.1371/journal.pone.0175869"
                       target="_blank" title="PDF opens in new window">PDF</a>
                  </li>
              </ul>
            </li>
    </ul>
  </div>


<script type="text/javascript">
  var articleDoi = "10.1371/journal.pone.0062170";
  $.ajax({
    url: "https://frontpage.plos.org/wp-json/collections-api/contains",
    data: {id: articleDoi},
    context: document.body,
    timeout: 10000,
    dataType: "json",
    success: function (result, textStatus, xOptions) {
      if (result.response == "success" && result.data.collections.length > 0) {
        var articleCollectionsTemplate = _.template($('#articleCollectionsTemplate').html());
        var articleCollectionsHTML = articleCollectionsTemplate(result.data)
        $('.collections-aside-container').append(articleCollectionsHTML);
      }
    }
  });
</script>

<script type="text/template" id="articleCollectionsTemplate">
  <h3>Included in the Following <% if (collections.length == 1) { %>Collection<% } else { %>Collections<% } %></h3>
  <ul id="collectionList">
  <% _.each(collections, function (collection) { %>
    <li>
      <a href="<%= collection.permalink %>"><%= collection.title %></a>
    </li>
  <% }); %>
  </ul>
</script>

<div class="aside-container collections-aside-container">
</div>


<div class="skyscraper-container">
  <div class="title">Advertisement</div>
<!-- DoubleClick Ad Zone -->
  <div class='advertisement' id='div-gpt-ad-1458247671871-1' style='width:160px; height:600px;'>
    <script type='text/javascript'>
      googletag.cmd.push(function() { googletag.display('div-gpt-ad-1458247671871-1'); });
    </script>
  </div>
</div>




<div class="subject-areas-container">
  <h3>Subject Areas <div id="subjInfo">?</div>
    <div id="subjInfoText">
      <p>For more information about PLOS Subject Areas, click
        <a href="https://github.com/PLOS/plos-thesaurus/blob/master/README.md" target="_blank" title="Link opens in new window">here</a>.</p>
      <span class="inline-intro">We want your feedback.</span> Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!


    </div>
  </h3>
  <ul id="subjectList">
      <li>
              <a class="taxo-term" title="Search for articles about Breast cancer"
                 href="/plosone/search?filterSubjects=Breast+cancer&filterJournals=PLoSONE&q=">Breast cancer</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Breast cancer"><p class="taxo-explain">Is the Subject Area <strong>"Breast cancer"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about MicroRNAs"
                 href="/plosone/search?filterSubjects=MicroRNAs&filterJournals=PLoSONE&q=">MicroRNAs</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="MicroRNAs"><p class="taxo-explain">Is the Subject Area <strong>"MicroRNAs"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Apoptosis"
                 href="/plosone/search?filterSubjects=Apoptosis&filterJournals=PLoSONE&q=">Apoptosis</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Apoptosis"><p class="taxo-explain">Is the Subject Area <strong>"Apoptosis"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Vimentin"
                 href="/plosone/search?filterSubjects=Vimentin&filterJournals=PLoSONE&q=">Vimentin</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Vimentin"><p class="taxo-explain">Is the Subject Area <strong>"Vimentin"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Cell proliferation"
                 href="/plosone/search?filterSubjects=Cell+proliferation&filterJournals=PLoSONE&q=">Cell proliferation</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Cell proliferation"><p class="taxo-explain">Is the Subject Area <strong>"Cell proliferation"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Slugs"
                 href="/plosone/search?filterSubjects=Slugs&filterJournals=PLoSONE&q=">Slugs</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Slugs"><p class="taxo-explain">Is the Subject Area <strong>"Slugs"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Cell cycle inhibitors"
                 href="/plosone/search?filterSubjects=Cell+cycle+inhibitors&filterJournals=PLoSONE&q=">Cell cycle inhibitors</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Cell cycle inhibitors"><p class="taxo-explain">Is the Subject Area <strong>"Cell cycle inhibitors"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Enzyme-linked immunoassays"
                 href="/plosone/search?filterSubjects=Enzyme-linked+immunoassays&filterJournals=PLoSONE&q=">Enzyme-linked immunoassays</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Enzyme-linked immunoassays"><p class="taxo-explain">Is the Subject Area <strong>"Enzyme-linked immunoassays"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
  </ul>
</div>
<div id="subjectErrors"></div>
  </aside>
</div>




</main>
<footer id="pageftr">
  <div class="row">
    <div class="block x-small">

<ul class="nav nav-secondary">
    <li class="ftr-header"><a href="https://plos.org/publications/journals/">Publications</a></li>
    <li><a href="/plosbiology/" id="ftr-bio">PLOS Biology</a></li>
    <li><a href="/plosmedicine/" id="ftr-med">PLOS Medicine</a></li>
    <li><a href="/ploscompbiol/" id="ftr-compbio">PLOS Computational Biology</a></li>
    <li><a href="/plosgenetics/" id="ftr-gen">PLOS Genetics</a></li>
    <li><a href="/plospathogens/" id="ftr-path">PLOS Pathogens</a></li>
    <li><a href="/plosone/" id="ftr-one">PLOS ONE</a></li>
    <li><a href="/plosntds/" id="ftr-ntds">PLOS Neglected Tropical Diseases</a></li>
  </ul>
    </div>
    <div class="block x-small">

<ul class="nav nav-secondary">
    <li class="ftr-header">&nbsp;</li>
    <li><a href="/climate/" id="ftr-climate">PLOS Climate</a></li>
    <li><a href="/digitalhealth/" id="ftr-digitalhealth">PLOS Digital Health</a></li>
    <li><a href="/globalpublichealth/" id="ftr-globalpublichealth">PLOS Global Public Health</a></li>
    <li><a href="/sustainabilitytransformation/" id="ftr-sustainabilitytransformation">PLOS Sustainability and Transformation</a></li>
    <li><a href="/water/" id="ftr-water">PLOS Water</a></li>
  </ul>
    </div>
    <div class="block xx-small">	


<ul class="nav nav-tertiary">
  <li>
    <a href="https://plos.org" id="ftr-home">Home</a>
  </li>
  <li>
    <a href="https://blogs.plos.org" id="ftr-blog">Blogs</a>
  </li>
  <li>
    <a href="https://collections.plos.org/" id="ftr-collections">Collections</a>
  </li>
  <li>
    <a href="mailto:webmaster@plos.org" id="ftr-feedback">Give feedback</a>
  </li>
  <li>
    <a href="/plosone/lockss-manifest" id="ftr-lockss">LOCKSS</a>
  </li>
</ul>
    </div>
    <div class="block xx-small">

<ul class="nav nav-primary">
  <li><a href="https://plos.org/privacy-policy" id="ftr-privacy">Privacy Policy</a></li>
  <li><a href="https://plos.org/terms-of-use" id="ftr-terms">Terms of Use</a></li>
  <li><a href="https://plos.org/advertise/" id="ftr-advertise">Advertise</a></li>
  <li><a href="https://plos.org/media-inquiries" id="ftr-media">Media Inquiries</a></li>
  <li><a href="https://plos.org/contact" id="ftr-contact">Contact</a></li>
</ul>
    </div>
  </div>
  <div class="row">
    <p>

<img src="/resource/img/logo-plos-footer.png" alt="PLOS" class="logo-footer"/>


<span class="footer-non-profit-statement">PLOS is a nonprofit 501(c)(3) corporation, #C2354500, based in San Francisco, California, US</span>    </p>
    <div class="block">

&nbsp;
<!--
  Webapp build:  3.7.29-SNAPSHOT at 20220301175124 by root, commit: addc5e2
  Service build: 2.6.0-SNAPSHOT at 20220222171921 by root, commit: 20f030d
  -->
    </div>
  </div>
 
<script src="/resource/js/global.js" type="text/javascript"></script>
</footer>




<script type="text/javascript">
  var ArticleData = {
    doi: '10.1371/journal.pone.0062170',
    title: '<article-title xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells<\/article-title>',
    date: 'Apr 24, 2013'
  };
</script>
<script src="/resource/js/components/show_onscroll.js" type="text/javascript"></script>
<script src="/resource/js/vendor/spin.js" type="text/javascript"></script>
<script src="/resource/js/pages/article.js" type="text/javascript"></script>
<script src="/resource/js/pages/article_sidebar.js" type="text/javascript"></script>
<script src="/resource/js/pages/article_references.js" type="text/javascript"></script>
<script src="/resource/js/vendor/foundation/foundation.dropdown.js" type="text/javascript"></script>
  <script src="/resource/js/components/table_open.js" type="text/javascript"></script>

        <script src="/resource/js/components/figshare.js" type="text/javascript"></script>
  <script src="/resource/js/vendor/jquery.panzoom.min.js" type="text/javascript"></script>
  <script src="/resource/js/vendor/jquery.mousewheel.js" type="text/javascript"></script>

  <script src="/resource/js/components/lightbox.js" type="text/javascript"></script>

  <script src="/resource/js/pages/article_body.js" type="text/javascript"></script>


<!-- This file should be loaded before the renderJs, to avoid conflicts with the FigShare, that implements the MathJax also. -->

<!--  mathjax configuration options  -->
<!-- more can be found at http://docs.mathjax.org/en/latest/ -->
<script type="text/x-mathjax-config">
MathJax.Hub.Config({
  "HTML-CSS": {
    scale: 100,
    availableFonts: ["STIX","TeX"],
    preferredFont: "STIX",
    webFont: "STIX-Web",
    linebreaks: { automatic: false }
  },
  jax: ["input/MathML", "output/HTML-CSS"]
});
</script>

<script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=MML_HTMLorMML"></script>

<div class="reveal-modal-bg"></div>
</body>
</html>
